
==== Front
Acta Pharm Sin B
Acta Pharm Sin B
Acta Pharmaceutica Sinica. B
2211-3835
2211-3843
Elsevier

S2211-3835(24)00228-4
10.1016/j.apsb.2024.05.032
Review
Enhancing cancer immunotherapy: Nanotechnology-mediated immunotherapy overcoming immunosuppression
Chen Yunna a†
Zhou Qianqian bc†
Jia Zongfang bc
Cheng Nuo bc
Zhang Sheng a
Chen Weidong wdchen@ahtcm.edu.cn
bc⁎
Wang Lei wanglei@ahtcm.edu.cn
bc⁎
a Key Laboratory of Molecular Biology (Brain diseases), Anhui University of Chinese Medicine, Hefei 230012, China
b MOE-Anhui Joint Collaborative Innovation Center for Quality Improvement of Anhui Genuine Chinese Medicinal Materials, Hefei 230012, China
c Anhui Province Key Laboratory of Chinese Medicinal Formula, Hefei 230012, China
⁎ Corresponding authors. wdchen@ahtcm.edu.cnwanglei@ahtcm.edu.cn
† These authors made equal contributions to this work.

03 6 2024
9 2024
03 6 2024
14 9 38343854
22 3 2024
12 5 2024
24 5 2024
© 2024 The Authors
2024
https://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Immunotherapy is an important cancer treatment method that offers hope for curing cancer patients. While immunotherapy has achieved initial success, a major obstacle to its widespread adoption is the inability to benefit the majority of patients. The success or failure of immunotherapy is closely linked to the tumor's immune microenvironment. Recently, there has been significant attention on strategies to regulate the tumor immune microenvironment in order to stimulate anti-tumor immune responses in cancer immunotherapy. The distinctive physical properties and design flexibility of nanomedicines have been extensively utilized to target immune cells (including tumor-associated macrophages (TAMs), T cells, myeloid-derived suppressor cells (MDSCs), and tumor-associated fibroblasts (TAFs)), offering promising advancements in cancer immunotherapy. In this article, we have reviewed treatment strategies aimed at targeting various immune cells to regulate the tumor immune microenvironment. The focus is on cancer immunotherapy models that are based on nanomedicines, with the goal of inducing or enhancing anti-tumor immune responses to improve immunotherapy. It is worth noting that combining cancer immunotherapy with other treatments, such as chemotherapy, radiotherapy, and photodynamic therapy, can maximize the therapeutic effects. Finally, we have identified the challenges that nanotechnology-mediated immunotherapy needs to overcome in order to design more effective nanosystems.

Graphical abstract

Nanomedicine activates anti-tumor immunity by regulating immune cells, thereby remodeling the immunosuppressive microenvironment and enhancing anti-tumor efficiency.Image 1

Key words

Immunotherapy
Nanomedicine
Tumor immunosuppressive microenvironment
Cancer
T cells
Immunogenic cell death
Immune checkpoint inhibitors
Extracellular matrix
==== Body
pmc1 Introduction

Immunotherapy has become an effective approach to cancer treatment, aiming to inhibit tumor development by enhancing anti-tumor immune responses1, 2, 3. The clinical success of impeding antibodies targeting cytotoxic T lymphocyte-associated antigen-4 (CTLA-4) and programmed death-1 (PD-1) suggests the advantages of immunotherapy in cancer treatment4, 5, 6. While immunotherapy has made significant progress in cancer treatment over the past two decades, it is only effective for a small number of people7. The formation of a tumor immunosuppressive microenvironment (TIME) is considered to be the primary cause of treatment failure8, 9, 10. Therefore, improving the TIME is an elegant strategy to facilitate the clinical implementation of cancer immunotherapy, capable of promoting antitumor immune responses to eradicate tumors.

Nanotechnology is an emerging cancer treatment that mainly relies on the “enhanced permeability and retention (EPR)” effect to deliver chemical drugs into tumors while minimizing accumulation in other tissues and reducing side effects11,12. EPR effects are not universal because of tumor heterogeneity13, 14, 15. The utilization of nanocarriers as delivery systems for chemical drugs was limited in cancer therapy. However, nanotechnology-mediated remodeling of the tumor microenvironment (TME) holds great promise in immunotherapy and is considered to be very useful in improving TIME16, 17, 18. Nanotechnologies participate in the remodeling of TIME by targeting immune cells, thereby enhancing their anticancer effect19,20. Nanotechnologies can also stimulate the immune system by promoting immunogenic cell death (ICD)21. Moreover, nanotechnologies can also be used in combination with other methods to simultaneously apply immunotherapy and combat cancer progression and metastasis.

In this review, we described the composition of TIME and the challenges it presents, as well as how nanotechnology can be utilized to overcome these challenges and improve immunotherapy. Our goal was to demonstrate that nanotechnology can not only be used to deliver chemotherapeutic drugs but also to inhibit tumor development by acting on TIME.

2 What is TIME?

A variety of immune and non-immune cells are present in the TME, contributing to immunosuppression, matrix deposition, and angiogenesis22, 23, 24 (Fig. 1 and Table 1). Among them, immune cells such as natural killer (NK) cells, lymphocytes, and dendritic cells (DCs) participate in suppressing tumor growth25, 26, 27. For example, NK cells kill tumor cells by recognizing their surface molecules28. The process of generating an immune response begins with immature DCs recognizing pathogens and maturing. Mature DCs then present antigens with the assistance of major histocompatibility complex (MHC) class I and II molecules to activate CD4+ and CD8+ T cells. However, the congenital immune system is suppressed, and systemic adaptive immune activation is disrupted in the TME29,30. The main reason for this phenomenon is the infiltration of immunosuppressive cells in the TME31. Cytokines secreted by common immunosuppressive cells, such as MDSCs, regulatory T cells (Tregs), and M2-type macrophages, interfere with the immune response. This result allows tumor cells to evade immune recognition and ultimately form TIME32, 33, 34. For example, tumor-associated macrophages (TAMs) promote T-cell failure by expressing the transcription factor interferon regulatory factor-8 (IRF8)35. The extracellular matrix (ECM) secreted by TAFs hinders T cells from entering the tumor36. Tregs maintain the M2 phenotype of TAMs by inhibiting the secretion of interferon-γ by CD8+ T cells37. The retinoic acid and transforming growth factors (TGF-β) secreted by MDSCs can convert CD4+ T cells into Tregs38. The current challenge for immunotherapy lies in the presence of TIME.Figure 1 The TIME composed of immune cells. Reprinted with the permission from Ref. 22. Copyright © 2022 FRONTIERS MEDIA SA.

Figure 1

Table 1 The composition and characteristics of TIEM.

Table 1Classification	Constituent	Characteristic	
Immune cells	DCs	Present antigens to T cells to initiate anti-tumor immunity	
T cells	Responsible for killing tumor cells	
NK cells	Responsible for killing tumor cells	
B cells	Directly or indirectly presenting antigens to T cells	
Non-immune cells	MDSCs	Inhibition of T cell activity	
Tregs	Prevent the anti-tumor response of immune cells	
TAFs	Generating ECM to inhibit T cell function	
TAMs	Including classically activated M1 macrophages and alternative activated M2 macrophages, M1 macrophages have anti-tumor effects, while M2 macrophages have pro-tumor effects	
DCs, dendritic cells; NK cells, natural killer cells; MDSCs, myeloid-derived suppressor cells; Tregs, regulatory T cells; TAFs, tumor-associated fibroblasts; TAMs, tumor-associated macrophage.

3 Tumor immunotherapy enhanced via nanotechnology

Currently, numerous nanomedicines are being utilized for cancer immunotherapy. Nanosystems can deliver immune modulators or genes to specific immune cells to stimulate the immune system. Importantly, some nanomaterials have the ability to regulate immune cells. In addition, the designability of nanosystems provides the possibility for the development of nanomedicines with specific functions. In summary, nanomedicines-mediated immunotherapy has great application prospects. Herein, we have summarized the research on the targeted regulation of immune cells by nanomedicines in Supporting Information Table S1.

3.1 Nanomedicine for targeting TAMs

TAMs are the primary cells responsible for regulating the immune microenvironment of tumors. They can be polarized into a classically activated M1 phenotype and an alternatively activated M2 phenotype. Macrophages are generally considered a “double-edged sword” in cancer treatment. M1 macrophages have tumor growth-suppressing effects, while M2-type macrophages have tumor growth-promoting effects39. Notably, TAMs are predominantly of the M2-type in the TME, contributing to the development of immunosuppression40,41. Therefore, repolarization of TAMs may be an effective method to inhibit M2 macrophage infiltration in tumors and improve TIME42. Recently, there has been significant interest in nanomedicine for regulating the repolarization of TAMs (Fig. 2A and B).Figure 2 Schematic illustration of the repolarization mechanism of TAMs mediated by nanotechnology. (A) Nanotechnology triggers the repolarization of M2 TAMs to M1 TAMs, thereby activating the anti-tumor immunity of T cells and providing opportunities for remodeling TIME. (B) The mechanism by which nanotechnology promotes the repolarization of M2 TAMs mainly involves the activation of NF-κB p65, promotes cytokine release and inhibits CSF1R signaling.

Figure 2

3.1.1 Nanomedicine modulates the nuclear factor-kB (NF-κB) pathway involved in repolarizing TAMs

NF-κB is a dimeric transcription factor composed of two of the five protein family members. It can play a pivotal role in immunity by regulating the expression of chemokines, cytokines, proteins, etc43. In tumor progression, the NF-κB pathway is considered a key regulator of TAMs polarization44,45. The activation of NF-κB in macrophages is a critical factor for tumor occurrence and development. Regulating the NF-κB pathway can lead to the repolarization of M2 TAMs46. Therefore, utilizing nanotechnology to target the NF-κB pathway is an effective approach for reducing M2 macrophages in TME and enhancing the response to tumors.

Methotrexate (MTX) is widely used for its effective anti-tumor and anti-inflammatory effects47,48. To enhance the delivery efficiency of MTX, researchers developed poly (lactic acid)-glycolic acid (PLGA) nanoparticles encapsulated with polyethyleneimine (Pei) and hyaluronic acid (HA) loaded with MTX, known as HA-PeiPLGA-MTX NPs49. After the administration of HA-PeiPLGA-MTX NPs, the NF-κB signaling pathway was inhibited, resulting in a transition of M2 TAMs to the M1 phenotype. Ultimately, the nanoparticles enhanced the immune response and inhibited the growth of breast cancer. PI3 kinase γ (PI3-kinase γ, PI3K γ) is a crucial molecule found in macrophages involved in the immune response to tumors. PI3K γ can participate in regulating tumor immune suppression by inhibiting NF-κB p65. Therefore, selectively suppressing the expression of PI3K γ using PI3K γ inhibitors is a method to enhance the tumor immune response. Li et al.50 prepared porous hollow iron oxide nanoparticles modified with mannose for loading PI3K γ small molecule inhibitors (3-methyladenine, 3-MA). The prepared nanoparticles can target TAMs and activate NF-κB p65, promoting the polarization of TAMs into M1-type macrophages. IMD-0354 is a specific inhibitor of the NF-κB pathway, which effectively suppresses the NF-κB pathway to achieve repolarization of M2 TAMs. Thus, Liu et al.51 first prepared mannose-modified lipid nanoparticles loaded with IMD-0354 (M-IMD-LNP). Next, nanogels responsive to matrix metalloproteinase 2 (MMP2) (P/ML-NNG) were used to encapsulate the PD-1 antibody and M-IMD-LNP. P/ML-NNG can release drugs to different targets and simultaneously inhibit the PD-1/PD-L1 and NF-κB pathways, thereby repolarizing M2 macrophages to M1 macrophages. The assessment of anti-tumor immunity confirmed that P/ML-NNG can effectively enhance the immune response and improve the effectiveness of immunotherapy. MicroRNA-155 (miR155) is a potent regulatory factor for immune cell function, effectively influencing TAMs polarization and enhancing tumor immunotherapy. In order to achieve effective delivery of miR155, researchers have developed layered double hydroxides (LDHs) nanoparticles52. LDH@155 nanoparticles effectively activated NF-κB expression in TAMs, induced polarization of TAMs towards the M1 phenotype, and enhanced the efficacy of anti-PD-1 antibody immunotherapy (Fig. 3).Figure 3 The anti-tumor efficacy of LDH@155 combined with chemotherapy and immunotherapy. (A) Tumor growth curves of LDH@155 combined with α-PD-1. (B) Tumor growth curves of LDH@155 combined with Carboplatin. (C) Kaplan–Meier survival curves of LDH@155 combined with α-PD-1. (D) Kaplan–Meier survival curves of LDH@155 combined with Carboplatin. Reprinted with the permission from Ref. 52. Copyright © 2019 John Wiley and Sons. ∗P < 0.05; ∗∗P < 0.01; ∗∗∗P < 0.001.

Figure 3

The primary method for nanomedicine to regulate NF-κB is by encapsulating NF-κB inhibitors into nanocarriers, thus effectively delivering the inhibitors to the tumor sites. Compared to using inhibitors alone, the intervention of nanomedicines increases the accumulation of inhibitors at the tumor site, leading to more TAMs being repolarized to the M1 phenotype.

3.1.2 Nanomedicine regulation of cytokines involved in TAMs repolarization

Cytokines are classified as small signaling proteins and comprise a family of proteins, including interleukins, lymphokines, chemokines, single factors, and interferons53. Cytokines are crucial components of the immune system and serve as biomarkers for various diseases54,55. Therefore, regulating cytokine expression can help improve TIME.

IL-12 is a heterodimeric cytokine that regulates the transformation of M2 macrophages into M1 macrophages, resulting in anti-tumor responses56. The microenvironment-responsive nanocarriers containing IL-12 were engulfed by macrophages, leading to the release of IL-12. This promoted the repolarization of TAMs into the M1 phenotype and exhibited significant anti-tumor effects57. The combination of IL-12 and chemotherapy drugs in cancer treatment has garnered increasing attention. Li et al.58 developed therapeutic nanoparticles (TNPs) for the co-delivery of IL-12 and doxorubicin. Doxorubicin and IL-12 were co-released in TME. The released IL-12 promoted the polarization of TAMs into the M1 phenotype, enhancing the anti-tumor effectiveness of doxorubicin.

Macrophage colony-stimulating factor (MCSF) participates in macrophage recruitment and facilitates polarization into M2 macrophages by binding to the CSF1R and transmembrane type III protein tyrosine kinase receptor found on macrophages and monocytes59, 60, 61. Overall, targeted inhibition of CSF1R signaling is a promising immunotherapy strategy that promotes the repolarization of M2 macrophages into an anti-tumor M1 phenotype.

BLZ945 is a small molecule CSF1R inhibitor that can effectively repolarize M2 macrophages into M1 macrophages62. Simultaneously loading BLZ945 and selumetinib (a MAPK signaling inhibitor) into supramolecular nanoparticles can continuously inhibit both CSF1R and MAPK signaling pathways, promoting the repolarization of M2 macrophages to the M1 phenotype63. Therefore, the simultaneous inhibition of CSF1R and MAPK signals is a valid tactic for macrophage-mediated immunotherapy. The PDL1/PD1 signaling pathway is also involved in the polarization of TAMs, in addition to the CSF1R axis. Studies have found that anti-PDL1 can increase iNOS and reduce arginase levels, thereby affecting the phenotype of TAMs64. The overexpression of PDL1 in TAMs is regulated by the activation of the CSF1/CSF1R pathway. Therefore, the PDL1/PD1 signaling pathway is considered a key player in assisting the CSF1R signaling pathway in regulating the polarization of TAMs. In response to this phenomenon, a system of self-assembled lipid nanoparticles loaded with small molecule inhibitors of the CSF1R signaling axis (BLZ945) and surface-modified by an anti-PDL1 monoclonal antibody (α-PDL1-CSF-LNPs) has been developed for anti-tumor research65. This system can target and inhibit the PDL1 and CSF1R pathways simultaneously, thereby promoting the transformation of the M2 phenotype into the M1 phenotype and enhancing the anti-tumor immune response.

Cytokines can participate in regulating TAMs polarization through various pathways. Loading cytokines or their inhibitors into nanosystems can simultaneously regulate multiple pathways to induce the polarization of TAMs into the M1 phenotype. Therefore, immunotherapy based on nanomedicines tends to incorporate cytokines and chemotherapy drugs into the nanosystem to exert synergistic anti-tumor effects.

3.1.3 Others

TMP195 is a specific class II HDAC small molecule inhibitor that repolarizes M2 macrophages into M1 macrophages by altering their epigenetic properties66. However, TMP195 may have potential side effects when applied in vivo. To tackle this issue, macrophage membrane-coated biomimetic nanoparticles were developed as delivery vehicles for TMP19567. The biomimetic nanoparticles repolarize M2 macrophages to M1 macrophages and synergize with photothermal therapy (PTT) to enhance anti-tumor effects. As a dual agonist of Toll-like receptor TLR7/8, R848 can promote the polarization of M2 macrophages towards M1 macrophages. Lignin biopolymers were used as carriers to prepare nanoparticles containing R848 (R848@LNPs) and labeled with 5 (6)-carboxyfluorescein (FAM)68. R848@LNPs can target CD206-positive M2-like TAMs and convert them into anti-tumor M1 macrophages. Therefore, when combined with vinblastine, R848@LNPs can stimulate immune cells in the TME to transition to an anti-tumor immune state, thereby enhancing the anticancer effect of vinblastine. Iron can promote the conversion of anti-inflammatory M2 macrophages into pro-inflammatory M1 macrophages. Research has shown that iron oxide nanoparticles can induce the differentiation of M2-like TAMs into M1 phenotypes, which can inhibit tumor growth69. Mitochondria not only produce energy for cells but also regulate cell survival and death. In the TME, mitochondria are involved in the regulation and activation of immune cells. It is worth noting that mitochondria are involved in regulating macrophage polarization. To this end, Zhao et al.70 developed twin-like charge-switchable nanoparticles that target mitochondria. The nanoparticles selectively silence mitofusin 1 (MFN1), thereby inhibiting mitochondrial fusion in TAMs and promoting the repolarization of TAMs from M2 to M1 phenotype. This drug delivery strategy effectively reversed TIME and provided an efficient solution for tumor immunotherapy. MicroRNA-125a (miR-125a), a non-coding RNA, participates in regulating immune cell function by binding to the 3′-untranslated region of targeted mRNA. Furthermore, miR-125a exhibits ideal tumor growth inhibitory effects. Accordingly, miR-125a may function as a genetic drug with dual effects, reversing TAMs polarization and inhibiting tumor growth. Researchers have developed polyethyleneimine-modified dendritic mesoporous silica nanoparticles loaded with miR-125a (DMSN-PEI@125a) to synergistically reverse immune suppression and kill tumor cells71. In TC-1 mouse models, DMSN-PEI@125a can repolarize TAMs to stimulate anti-tumor immune responses and synergistically inhibit tumor growth. The Cu-doped polypyrrole nanozyme modified with polyethylene glycol (CuPP), developed by Zeng et al.72, can increase oxygen levels in the TME and reverse the hypoxic conditions. More importantly, CuPP promotes the transformation of M2 macrophages into M1 macrophages, inducing a strong immune response. OX40L-overexpressed M1 macrophage exosomes (OX40L M1-exos) promoted the reprogramming of TAMs into M1 macrophages by activating the OX40/OX40L pathway73. This strategy effectively inhibited the growth and metastasis of breast cancer.

3.2 Nanomedicine for targeting T cells

T cells eliminate tumor cells based on their antigenic specificity and play a role in anti-tumor immune responses74,75. The function of T cells in regulating immune responses is mediated by CD4+ and CD8+ T cells, respectively76, 77, 78. Among them, CD8+ T cells kill tumor cells by recognizing the MHC I molecules expressed by tumor cells. CD4+ T cells can directly kill tumor cells through MHC II, or indirectly kill tumor cells by releasing cytokines to activate other immune cells with anti-tumor functions79. However, T cells encounter challenges in penetrating tumor tissue and unleashing their anti-tumor immune response because of various immunosuppressive mechanisms80. Currently, research on T cell therapy primarily focuses on increasing T cell infiltration into tumor sites, activating T cells, and enhancing their activity (Fig. 4)81, 82, 83.Figure 4 Schematic illustration presenting brief mechanism of nanomedicine targeting T cells. (1) After entering tumor tissues, nanomedicines silence the expression of TGF-β and CXCL1, reducing ECM deposition. Subsequently, the permeation of T cells at the tumor site increases, thereby regulating TIME. (2) The production of lactate decreases after the silencing of LDHA expression by nanomedicines. The reduction of lactate production induces the reversal of the acidic microenvironment of tumors, thereby restoring T cells immune function. (3) Nanomedicines reduce ROS level and promote T cells survival by catalyzing the decomposition of H2O2 within tumors.

Figure 4

3.2.1 Nanomedicine increases T-cell infiltration

The absence or mutation of the gene encoding the phosphatase and tensin homolog (PTEN), which is located on chromosome 10, is associated with reduced T-cell infiltration at tumor sites. Restoring PTEN function is expected to enhance T-cell infiltration at tumor sites. To accomplish this objective, nanoparticles loaded with PTEN messenger RNA (mRNA) have been developed to enhance PTEN expression in tumors84. There is no doubt that PTEN mRNA nanoparticles promote the infiltration of CD8+ T cells into tumor tissues and reverse TIME. In addition to the obstruction of T cell infiltration in tumors, T cell depletion is also a factor leading to the failure of immunotherapy85. Therefore, increasing T cell infiltration while preventing their depletion in tumors has become an important strategy for enhancing immunotherapy. The absence of sphingosine 1-phosphate receptor 1 (S1PR1) on the surface of T cells results in a considerable number of T cells being unable to infiltrate tumor tissue. Due to the internalization of S1PR1 dependent on G protein-coupled receptor kinase 2 (GRK2). Inhibiting GRK2 can stabilize the expression of S1PR1 on the outside of T cells. Meanwhile, blocking PD-1, T-cell immunoglobulin, and mucindomain-containing molecule-3 (TIM-3), cytotoxic T lymphocyte antigen-4 (CTLA-4) can reduce T cell depletion. Therefore, the combination of biomimetic nanoparticles and paroxetine (PX, a GRK2 inhibitor) reduced PD-1 and TIM-3 on T cells by downregulating TET2 levels and inhibited GRK2 to stabilize S1PR1 expression on the outside of T cells86. The combination of biomimetic nanoparticles and PX increased T cell infiltration at the tumor site and reversed their dysfunction (Fig. 5). The FeS-GOx nanodots synthesized by glucose oxidase self-assemble into FeS-GOx@PTX through hydrophilic interactions with paclitaxel87. FeS-GOx@PTX can promote T-cell infiltration and completely eliminate primary tumors by inducing ICD. The permeation efficiency of chimeric antigen receptor (CAR)-redirected T lymphocytes (CAR T cells) in solid tumors is low. PLGA nanoparticles loaded with indocyanine green (PLGA-ICG) can damage ECM by generating heat88. Subsequently, the infiltration of CAR T cells into the tumor increased, indicating a significant therapeutic effect on melanoma.Figure 5 (A) Schematic illustration of biomimetic nanoparticles and PX increase T cell infiltration in tumor. (B) The spleen weights of each group. (C) Images of CD3+ T cells in the spleens of mice from different groups (scale bar = 100 μm). (D, E) Bone marrow CD3+ T cells and their percentages in different groups of mice. (F, G) Bone marrow S1PR1+CD3+ T cells and their percentage in different groups of mice. Reprinted with the permission from Ref. 86. Copyright © 2023 John Wiley and Sons. ∗P < 0.05; ∗∗P < 0.01; ∗∗∗P < 0.001 (n = 5).

Figure 5

Ensuring that a sufficient number of T cells initiate an immune response at the tumor site requires not only increasing T cell infiltration but also reducing T cell depletion. Therefore, when designing nano-delivery systems, it is important to consider both increasing T cell infiltration and avoiding T cell depletion.

3.2.2 Nanomedicine activation of T cells

The acidic microenvironment resulting from the production of lactic acid in solid tumors hinders the immune response of T cells89, 90, 91. Specifically, the increase in lactate levels can lead to the inactivation and apoptosis of CD8+ T cells92. Therefore, reversing the acidic microenvironment of tumors caused by lactic acid can help restore the immune function of T cells93. A scheme for cancer treatment has been developed based on regulating tumor acidity using nanomedicine94. Lactate dehydrogenase A (LDHA) is primarily responsible for converting pyruvate to lactate, which contributes to tumor acidity. Silencing LDHA with small interfering RNA (siRNA) can help reverse tumor acidity and restore T cell anti-tumor function. Therefore, Zhang et al.95 developed vascular CLAN nanoparticles as a siRNA delivery system (VNPsiLdha) to silence LDHA in tumor cells. This treatment significantly reduced lactate production and neutralized tumor acidity. Ultimately, the infiltration of CD8+ T cells increased, and their functionality was restored, resulting in improved immunotherapy with anti-PD-1. Moreover, ROS secreted by immunosuppressive cells in TME can induce apoptosis and functional inhibition in T cells, leading to suboptimal T cell-mediated immunotherapy. Simultaneously stimulating T cell activation and regulating ROS levels in TME is a promising treatment approach. To achieve this goal, Lu et al.96 developed antibodies (anti-CD3/CD28 mAbs, CD) functionalized MnOx nanoparticles camouflaged with tumor cell membranes (CD-MnOx@CM) to regulate TME and activate T cells. As envisioned, CD-MnOx@CM not only effectively activated CD8+ T cells but also regulated ROS levels in TME by catalyzing the decomposition of H2O2 into O2, thereby promoting T cell survival within the tumor.

T cells need to be activated before they can function in immunotherapy. However, the function of T cells is often inhibited in TIME. The development of nanomedicines should not neglect the activation of T cells while considering increasing T cell infiltration.

3.3 Nanomedicine for targeting Tregs

Tregs, an important subgroup of CD4+ T cells, maintain immune homeostasis by suppressing immune responses97,98. The abnormal number and function of Tregs can lead to autoimmune diseases99. In tumor immunity, Tregs are involved in suppressing anti-tumor immune responses100. Tregs can induce tumor immune escape by blocking effector T cells and by inducing monocytes to differentiate into the M2 subtype, which promotes tumor growth and metastasis101,102. In addition, TGF-β secreted by Tregs restricts immune cells from reaching TME, ultimately leading to TIME. Inhibiting or eliminating Tregs has become a key focus in promoting an anti-tumor immune response (Fig. 6).Figure 6 Schematic illustration of nanomedicines targeting Tregs to increase T cells immune response. Regulation of different nanomedicines (tLyp1-hNPs, LBL hNPs, UA liposomes, and iron oxide nanoparticles).

Figure 6

3.3.1 Nanomedicine inhibition of Tregs

Glutathione (GSH) is a key participant in maintaining the expression of Foxp3 in Tregs and their immunosuppressive function103. Furthermore, a hypoxic TME can not only recruit Tregs infiltration but also promote Tregs proliferation104,105. Consequently, some researchers have proposed overcoming Tregs-mediated immunosuppression by regulating the redox metabolism of the TME. Fluorine-assembled nanoparticles have been developed to overcome Tregs-mediated immunosuppression106. Herein, the oxygen contained in perfluorocarbon within fluorine-assembled nanoparticles can effectively alleviate hypoxia in the TME, thereby inhibiting the proliferation and infiltration of Tregs. On the other hand, the chemical prodrugs released by fluorine-assembled nanoparticles under laser irradiation reduce the level of GSH, thereby decreasing the expression of Foxp3 in Tregs, and accomplishing the objective of reversing tumor immune suppression. Imatinib (IMT) can decrease the quantity of Tregs and hinder their function by disrupting STAT3 and STAT5 signals. In order to accurately deliver IMT to Tregs, hybrid nanoparticles coupled with tLyp1 peptide were prepared for the delivery of IMT107. As expected, the tLyp1 peptide-coupled hybrid nanoparticles blocked the phosphorylation of STAT3 and STAT5, resulting in a decrease in Tregs within the tumors. Mitogen-activated protein kinase (MEK)/extracellular signal-regulated kinase (ERK) signaling is a prospective target for inducing the expansion of Tregs. Demethylcantharidin (DMC) can interfere with FOXP3 expression by inhibiting protein phosphatase 2A (PP2A), thereby reducing Treg levels in TME. Researchers have utilized DMC-conjugated β-cyclodextrin to create supramolecular photodynamic nanoparticles for the smart delivery of photosensitizers and immunomodulators108. The results showed that supramolecular photodynamic nanoparticles reduced Treg levels in TME and increased infiltration of CD8+ T cells, thereby reversing TIME. Of course, some researchers have combined the anti-tumor efficacy of PDT with the downregulation of Tregs in tumors by IMT. In this strategy, layer-by-layer hybrid nanoparticles (LBL-hNPs) were used to encapsulate IR-780 and IMT, thereby achieving dual effects of downregulating Tregs and exerting anti-tumor activity109. The results showed that LBL-hNPs reduced the inhibitory function of Tregs and improved the anti-tumor efficacy of PDT. Curcumin is an inhibitor of the MEK/ERK signaling pathway and can effectively reduce the increase of Tregs in tumors when loaded into nanoparticles (Fig. 7)110. In addition, ursolic acid (UA) is a lead compound with immune regulatory properties derived from plants and fruits. UA liposomes can reduce tumor-infiltrating Tregs by inhibiting STAT5 phosphorylation and IL-10 secretion111.Figure 7 Curcumin nanoparticles inhibit Tregs expansion. (A) Scanning and transmission electron microscopic images of curcumin and curcumin nanoparticles (left panel). Fluorescence images of carrier, curcumin, and curcumin nanoparticles in 4T1 cells (right panels), green fluorescent: curcumin. (B) Diagram of the relationship between average fluorescence intensity and time. (C) In vitro cell viability of normal peripheral blood monocytes and 4T1 cells. (D) Percentage of CD4+ CD25+ FoxP3+ Tregs induced in tumour-draining lymph nodes (left panel) and tumour-infiltrating lymphocytes of curcumin/nano-curcumin-treated (right panel) (n = 5). (E) The expression level of proteins. Reprinted with the permission from Ref. 110. Copyright © 2015 John Wiley and Sons.

Figure 7

Tregs expressing Foxp3 are abundant in the TME and are often associated with a poor prognosis. Interfering with Foxp3 expression is an effective approach to suppress Tregs and boost immune response. Therefore, the current nanomedicine design focuses on interfering with Foxp3 expression.

3.3.2 Nanomedicine elimination of Tregs

Considering that Tregs in tumor tissue are more closely associated with tumor immunosuppression, it is more effective to eliminate Tregs only at the tumor site than throughout the entire body. Nanoparticle-mediated PTT is widely used for local anticancer treatment, but its ability to eliminate Tregs has been neglected112, 113, 114. Therefore, nanoparticle-mediated PTT may be an effective method for locally eliminating Tregs and promoting immunotherapy. To verify this hypothesis, iron oxide nanoparticle-mediated PTT was used in mouse breast tumor models to investigate its combined anti-tumor effect with CTLA-4115. The results showed that iron oxide nanoparticle-mediated PTT can selectively eliminate Tregs at the tumor sites and enhance the inhibition of CTLA-4 on tumor growth.

It is worth noting that Tregs are responsible not only for suppressing tumor immunity but also for maintaining immune balance in the body116. Eliminating systemic Tregs may disrupt the body's immune balance and trigger certain autoimmune diseases117. In addition, eliminated Tregs rapidly release adenosine triphosphate (ATP) and convert it into adenosine near death. Afterward, adenosine binds to the surface receptors of T cells to inhibit their activity118. Hence, the treatment strategy of eliminating systemic Tregs to reverse immune suppression may not yield the anticipated results.

3.4 Nanomedicine for targeting MDSCs

MDSCs are immature bone marrow cells with immunosuppressive effects and play an essential role in TIME119,120. MDSCs primarily play a role in immune suppression by depleting metabolites, upregulating ROS, and secreting various cytokines121. MDSCs also play a role in inhibiting the immune function of T cells122. In recent years, nano-immunotherapy has primarily improved anti-tumor effectiveness by decreasing the activity of MDSCs or inhibiting their recruitment (Fig. 8).Figure 8 Schematic illustration of the mechanisms of nanotechnology regulating MDSCs.

Figure 8

3.4.1 Nanomedicine reduces the activity of MDSCs

Scavenger receptor type B-1 (SCARB1) is a high-affinity receptor for globular high-density lipoproteins (HDL) and is expressed in MDSCs. Focusing on this feature, researchers synthesized high-density lipoprotein nanoparticles (HDL NPs) for the specific targeting of SCARB1123. The results suggested that HDL NPs significantly inhibited the activity of MDSCs and suppressed tumor growth. Tadalafil is expected to regulate anti-tumor immunity by inhibiting the function of MDSCs. Therefore, Zhang et al.124 used nanotechnology to co-deliver tadalafil and indocyanine green, referred to as FIT NPs. The released tadalafil can effectively inhibit the activity of MDSCs at the tumor sites and enhance the therapeutic efficiency of PTT.

The immunosuppressive network composed of MDSCs inhibits the anti-tumor response of T cells, thereby promoting tumor immune escape. The main treatment method for MDSCs is to leverage the benefits of nanosystems to precisely deliver drugs into TME and suppress MDSC activity.

3.4.2 Nanomedicine inhibits the recruitment of MDSCs

Tumor hypoxia, as a characteristic marker of TME, activates TIME by recruiting MDSCs125. Researchers attempted to overcome the challenge caused by tumor hypoxia by interfering with mitochondrial respiration. Specifically, IR780 (a photosensitizer) and metformin (a mitochondrial respiratory inhibitor) were loaded onto the nanoplatforms simultaneously. The nanoplatforms released IR780 and metformin upon reaching the tumor site. The released metformin overcame tumor hypoxia by inhibiting mitochondrial respiration, thereby inhibiting the immunosuppressive function induced by MDSCs. Additionally, the accumulated O2 enhanced the anti-tumor therapy mediated by IR780126. Three negative breast cancer cells primarily depend on glycolysis (known as the “Warburg” effect) to acquire the energy required for growth. LDHA is highly expressed in glycolysis to facilitate the conversion of pyruvate to lactate. In addition, high LDHA expression promotes the recruitment of MDSCs by inducing the secretion of granulocyte colony-stimulating factor (G-CSF) and granulocyte macrophage colony-stimulating factor (GM-CSF). Based on this, researchers developed a redox reaction nanoassembly system (R-mPDV/PDV/DOX/siL) to silence LDHA and induce ICD127. R-mPDV/PDV/DOX/siL respond to the release of siRNA in tumors, enabling efficient silencing of LDHA. After silencing the expression of LDHA, the secretion of G-CSF and GM-CSF cytokines decreased, and the recruitment of MDSCs was inhibited. In summary, R-mPDV/PDV/DOX/siL have significant anti-tumor effects on 4T1 tumors.

Preventing MDSCs from entering TME is another strategy for initiating immunotherapy. Nanomedicines primarily inhibit the recruitment of MDSCs by impeding the key process of attracting MDSCs into the TME.

3.5 Nanomedicine for targeting TAFs

TAFs are one of the most abundant cells in the tumor matrix and play a crucial role in the development and metastasis of tumors128,129. Additionally, TAFs are the primary factor affecting TIME130,131. Specifically, the cytokines, chemokines, and cell surface proteins secreted by TAFs directly limit the infiltration of immune cells. TAFs can indirectly impede the infiltration of immune cells by producing ECM deposition. The direct elimination of TAFs may cause the spread of cancer cells, facilitating the invasion and metastasis of cancers. Therefore, reprogramming active TAFs into a quiescent state for fine-tuning therapy is an optimal approach to stimulate tumor immune responses. Nanodelivery systems are commonly used to regulate TAFs and enhance immune response due to their capability to efficiently penetrate tumor lesion areas (Fig. 9)132,133.Figure 9 Schematic illustration of nanomedicine regulation of TAFs. Nanomedicine reverse activated TAFs to resting state, thereby reducing ECM deposition in tumor tissue. Then, the “cold” tumor transforms into a “hot” tumor, increasing the efficacy of immunotherapy.

Figure 9

Relaxin (RLN) has the effect of inhibiting TAFs activation and improving TIME. Researchers synthesized a PolyMet-pRLN complex using the plasmid RLN (pRLN) and the polymer metformin (PolyMet) to overcome the short half-life of RLN134. To enhance the stability of the complex, lipid poly-γ-glutamic acid (PGA)/PolyMet-pRLN nanoparticles (LPPR) were further prepared. LPPR can effectively penetrate 4T1 luc/TAFs tumor spheres and inhibit the proliferation of TAFs. Furthermore, LPPR can increase the permeation of cytotoxic T cells and reduce the recruitment of immunosuppressive cells by suppressing the activation of TAFs in vivo. In brief, LPPR can remodel the immune microenvironment of triple negative breast cancer and elevate the anti-tumor efficacy of PD-L1 antibody. The release of trypsin (TPS) by mast cells can elevate the expression of α-smooth muscle actin (α-SMA) to activate TAFs. Based on this, He et al.135 developed tryptase-imprinted nanoparticles (DMSN@MIPs) using dendritic mesoporous silica as a carrier and TPS as the template molecule to neutralize TPS and inhibit TAFs activation. In addition, DMSN@MIPs suppressed the activation of TAFs and enhanced the penetration of doxorubicin liposomes (DOX/LIP) in tumors. As expected, the combination therapy of DMSN@MIPs and DOX/LIP significantly increased the levels of immune cells (including DCs, CD8+ T cells, and NK cells) and remodeled TIME.

In recent years, the active ingredients of traditional Chinese medicine have frequently been utilized as regulators of the tumor immune microenvironment in combination with chemotherapy drugs for anti-tumor treatment136,137. However, challenges such as poor water solubility and a short half-life in vivo limit the advancement of active ingredients in traditional Chinese medicine138. Therefore, many researchers have incorporated nano-delivery systems into the development of active ingredients139. For example, baicalin extracted from the roots of Scutellaria altissima L., has anti-fibrotic effects in various organs. Therefore, Zheng et al.140 constructed mPEG-modified poly (lactide-co-glycolide) (PLGA) nanoparticles loaded with baicalin (PMs-Ba). PMs-Ba can enhance the infiltration of cytotoxic T cells and stimulate the tumor immune microenvironment by inhibiting the activation of TAFs. Furthermore, PMs-Ba can significantly elevate the capacity of doxorubicin nanoparticles. Danshen-derived salvianolic acid B (SAB) also exhibits anti-fibrotic effects in various organs. In order to prolong the half-life of SAB in vivo, PEG-modified liposomes were used to encapsulate SAB (PEG-SAB-Lip)141. The research results indicate that PEG-SAB-Lip can inhibit the activation of TAFs by suppressing TGF-β1, thereby reducing collagen deposition at the tumor sites. After improving the tumor fibrosis microenvironment, CD4+ and CD8+ T cells, along with M1 macrophages, were recruited to the tumor sites, resulting in modulation of the TIME. In summary, the active components of traditional Chinese medicine are effective remedies for stimulating tumor immunity and enhancing the anti-tumor effects of chemotherapy drugs.

The occurrence of dynamic immune evasion can lead to a poor response to immune therapy. The induction of fibrosis by TAFs and the failure of T cells mediated by tumor cells are key factors contributing to dynamic immune evasion. In response to this discovery, Pan et al.142 developed a self-adaptive nanoregulator based on peptide-drug conjugates to alleviate dynamic immune evasion in pancreatic ductal adenocarcinoma (PDAC). This self-adaptive nanoregulator can achieve morphological transformation from spherical micelles to nanofibers to spherical nanoparticles. The self-adaptive nanoregulator disrupted tumor fibrosis by delivering an inhibitor of TAFs. In addition, this self-adaptive nanoregulator can also deliver an indoleamine 2,3-dioxygenase 1 inhibitor to alleviate the dysfunction of T cells induced by the IDO1-kynurenine axis. In summary, the self-adaptive nanoregulator can stimulate sustained anti-tumor immunity and enhance anti-tumor effectiveness. TAFs are compelled to act as “energy factories” for cancer cells, supplying energy for their rapid growth and proliferation. The glycolytic metabolite lactate produced by TAFs leads to impaired immune cell function, ultimately resulting in TIME. Therefore, simultaneous inhibition of glycolysis in cancer cells and TAFs may be crucial for the functioning of immune cells. Zang et al.143 modified the hybrid membrane of cancer cells and TAFs on solid lipid nanoparticles encapsulated with paclitaxel (a chemotherapy drug) and PFK15 (a glycolytic inhibitor). They aimed to target cancer cells and TAFs, respectively, and to block the metabolic network between them. Biomimetic nanoparticles simultaneously blocked the glycolysis of cancer cells and TAFs decreased lactate production in the TME, and stimulated immune responses. Furthermore, biomimetic nanoparticles have been demonstrated to enhance tumor growth inhibition. This suggests that disrupting the glycolysis of cancer cells and TAFs is a promising strategy for enhancing the anti-tumor immune response and improving the effectiveness of chemotherapy when combined with immunotherapy.

Notably, recent studies have also reported that TAFs may inhibit tumor growth. Completely eliminating TAFs may promote tumor growth and metastasis. Therefore, the goal of nanomedicine is to inhibit the activity of TAFs or partially eliminating eliminate them.

3.6 Nanomedicine for targeting NK cells

NK cells are a type of innate lymphocytes that have the ability to eliminate tumor cells and inhibit tumor development144. NK cells can not only kill tumor cells but also enhance the anti-tumor effects of other immune cells, such as DCs, CD8+ T cells, and macrophages145. Therefore, its role in cancer immunotherapy has gradually attracted the attention of researchers. It is worth noting that the cytotoxicity of NK cells in TME is the main factor determining its therapeutic effect146. However, NK cell toxicity is easily suppressed in TIME. Recent studies have shown that nanotechnology-mediated immunotherapy can activate NK cells to enhance cancer immunotherapy.

The anti-tumor activity of NK cells is inhibited by the immunosuppressive molecule TGF-β in TME. Galunisertib can counteract the inhibitory effect of TGF-β on NK cells by blocking TGF-β receptor type I kinase. Interleukin-15 (IL-15) can activate NK cells, thereby improving anti-tumor efficiency. Therefore, it is necessary to develop a nanosystem that can simultaneously deliver galunisertib and IL-15. Herein, Sun et al.147 prepared nanoparticles loaded with galunisertib and IL-15 using calcium carbonate as the core and sodium alginate as the outer layer (Gal/IL-15@CaLN). Gal/IL-15@CaLN can promote drug retention in tumors and activate NK cells, ultimately enhancing anti-tumor immune responses. In addition to directly targeting TGF-β, downstream signaling pathways such as transcription factors Smad2 and Smad3 can also be targeted to activate NK cells. SIS3 is a small molecule inhibitor of Smad3 that can be used to interfere with TGF-β-induced immunosuppression. A self-carried nanodrug-SIS3 (SCND-SIS3) enhances NK cell-mediated immune response by inhibiting Smad3-mediated Ndrg1 transcription148. The STING pathway activates NK cells by inducing the production of type I interferon (IFN), thereby inhibiting metastatic renal cell carcinoma. STING-loaded lipid nanoparticles can significantly activate NK cells and kill circulating metastatic cancer cells149. The cellular activity of NK cells is influenced by Src homology 2 domain-containing protein tyrosine phosphatase-1 (SHP-1), Cb1-b, and c-Cb1. In response to this phenomenon, lipid-based nanocarriers have been developed for encapsulating siRNA to target interference with SHP-1, Cb1-b, and c-Cb1150. The research results showed that nanoparticles safely and effectively silenced the expression of SHP-1, Cb1-b, and c-Cb1 in NK cells, thereby enhancing the ability of NK cells to kill cancer cells. In addition, the oxidative metabolites of self-assembled selenopeptide nanoparticles (SeNPs) can activate NK cells and enhance the anti-tumor efficacy of chemotherapy drugs (Fig. 10)151. The selenite produced through the self-assembly of β-selenate ester and Pem nanoparticles can inhibit the activation of NK cells by human leukocyte antigen E152. Overall, activating NK cells is an effective strategy for nanomedicines to stimulate anti-tumor immune responses.Figure 10 (A) Schematic illustration of the Sep/DOX formation. (B) Sep/DOX improve NK cells mediated immunotherapy. Reprinted with the permission from Ref. 151. Copyright © 2022 John Wiley and Sons.

Figure 10

The anti-tumor activity of NK cells is regulated by multiple pathways. Currently, the developed nanomedicines only focus on one pathway. In the future, we should develop a strategy to simultaneously target multiple pathways to activate NK cells and induce anti-tumor immunity.

3.7 Nanomedicine for targeting DCs

DCs are functionally specific antigen-presenting cells responsible for coordinating innate and adaptive immune responses153. The anti-tumor response of DCs mainly relies on transporting tumor-related antigens to draining lymph nodes to activate T-cell immune responses. Maturation of DCs is a necessary condition for presenting immune response signals to T cells. In tumors, the maturation process of DCs is often inhibited, preventing T cells from initiating anti-tumor immunity. Promoting the maturation of DCs is an effective strategy for enhancing T-cell immune responses and improving the clinical efficacy of cancer immunotherapy.

The initiation of anti-tumor immunity by DCs involves multiple steps, including ICD, recruitment of DCs, and presentation of antigen signals. Designing a type of nanoplat that simultaneously regulates these steps is an urgent need to enhance anti-tumor immune responses. The nanosystem (CC-6td NP) composed of chlorin e6 (Ce6), celecoxib, and 6-thio-2ʹ-deoxyguanosine (6-thio-dG) can achieve the ideal of simultaneously regulating the DCs anti-tumor immune response cascade step154. Among them, Ce6 is responsible for stimulating ICD, celecoxib recruits DCs by inducing the production of chemokine CCL5, and 6-thio-dG is responsible for enhancing the antigen cross-presentation ability of DCs. The designed nanosystem enhances the immune response of tumors and inhibits the growth and postoperative recurrence of colon cancer. Manganese (Mn) is crucial for human health as a nutritional trace element. Mn can promote the maturation of DCs and trigger the anti-tumor immune responses of T cells by activating the cGAS–STING pathway. Therefore, Wang et al.155 developed cancer cell membrane-modified Mn hydroxide nanoparticles for loading doxorubicin (mHMnO-Dox) to exert synergistic anti-tumor effects. The Mn2+ released by mHMnO-Dox promotes the maturation of DCs by activating cGAS-STING, which in turn increases the homing of T and NK cells, ultimately inducing anti-tumor immune responses. The mature DCs membrane activated by tumor antigens (αDCM) retains the ability to present antigens and can enhance the anti-tumor immune response of T cells. Therefore, encapsulating αDCM on the surface of poly (lactic-co-glycolic acid) loaded with rapamycin (aDCM@PLGA/RAPA) is a simple and efficient strategy for improving immunotherapy156. aDCM@PLGA/RAPA can stimulate the maturation of DCs and activate T-cell infiltration, ultimately inhibiting the progression of glioma in situ. In addition, polymer nanoparticles (PAG/BTZ) prepared by combining bortezomib (BTZ) and aminoguanidine (AG) modified polymer nanocarriers through electrostatic adsorption can respond to the release of BTZ and AG in vivo157. The released BTZ is responsible for inducing ICD, while AG is responsible for promoting the maturation of DCs, thereby enhancing the induction of anti-tumor immune responses. Certain chemotherapy drugs can activate anti-tumor immune responses. Therefore, RNA extracted from cancer cells treated with chemotherapy drugs can stimulate the maturation of DCs and induce anti-cancer immune responses. Su et al.158 prepared composite nanoparticles (RNA NPs) by electrostatically binding induced RNA with protamine to promote the maturation of DCs and enhance the efficacy of immune checkpoint inhibitors (ICIs).

Although activating DCs can induce anti-cancer immune responses, relying solely on DCs has limited inhibitory effects on cancer. Therefore, currently developed nanomedicines mostly combine immunotherapy with chemotherapy.

3.8 Nanomedicine for targeting tumor-associated B cells (TABs)

Compared to other immune cells, the role of TABs in anti-tumor immunity is often overlooked159. In the tertiary lymphoid structure, TABs are activated and present tumor-associated antigens to T cells to kill tumor cells160. In addition, TABs can indirectly regulate the anti-tumor response of T cells by producing antibodies. However, almost no nanomedicine specifically targeting TABs has been developed. Similar to TAMs, TABs can promote and inhibit tumor growth. At present, it is unclear how to distinguish between different types of TABs. Therefore, the future development of nanomedicines can focus on targeting different types of TABs.

3.9 Non-specific targeted nanomedicine

In addition to targeting a specific immune cell, some nanomedicines can non-specifically target different immune cells to initiate anti-tumor immunity. For example, the combination of nanomedicine-mediated PDT and immunotherapy enhances anti-tumor efficiency. Nanomedicine enhances the homing of anti-tumor immune cells by remodeling ECM.

3.9.1 Nanomedicine-mediated PDT

Reactive oxygen species (ROS), which are byproducts of oxygen consumption and cellular metabolism, are important factors in cancer growth and progression. ROS not only affects the polarization of macrophages in TME but also influences the maturation of DCs161. Under illumination, PDT can activate the immune response and promote tumor cell apoptosis by producing ROS through photosensitizers162. Therefore, PDT combined with immunotherapy is receiving increasing attention. Two-dimensional sheet-like nanocarriers exhibit unique optical properties and are ideal for drug loading. Therefore, Liu et al.163 prepared ruthenium nanoparticles to load BLZ-945 (a small molecule inhibitor of the CSF-1/CSF-1R pathway) and indocyanine green (Ru@ICG BLZ NPs). Ru@ICG-BLZ NPs facilitated the repolarization of TAMs to the M1 phenotype and eliminated tumor cells through phototherapy. PDT can lead to the upregulation of hypoxia-inducible factor 1α (HIF-1α), thereby promoting TIME and immune escape. HIF-1α, as a crucial transcriptional activator, can regulate the polarization of TAMs towards the M2 phenotype, which promotes tumor growth and limits the effectiveness of PDT. Therefore, the combination of PDT and anti–HIF–1α is an effective strategy for promoting tumor immune response. Curcumin is a bioactive compound extracted from the rhizome of Curcuma longa. It can significantly reduce the level of HIF-1α in tumor cells. It is worth noting that curcumin can also act as a photosensitizer to yield ROS under laser irradiation in vitro. Therefore, curcumin was embedded into NIR-triggered core-satellite upconverting nanoparticles (Cur-CSNPs) to achieve the dual effects of PDT and HIF-1α reversal164. The results showed that Cur-CSNPs mediated PDT repolarized M2 macrophages to M1 macrophages, initiating synergistic immunotherapy and inhibiting 4T1 tumor growth. The hydrophilic molecule zoledronic acid (Zol) is frequently utilized to enhance immune suppression caused by TAMs. The combination of Zol and PDT can achieve dual effects by promoting tumor immune response and inhibiting tumor growth. In order to accurately deliver Zol and photosensitizer (IR780) to TAMs and tumor cells, Jian et al.165 designed Mn dioxide (MnO2)-embedded and LyP-1 peptide-labeled liposomal nanoparticles for encapsulation of Zol and IR780 (Lipo Zol/IR NPs). Lipo Zol/IR NPs release Zol in TEM and are selectively engulfed by TAMs, causing them to repolarize from the immunosuppressed M2 macrophages to the immunostimulated M1 macrophages. Simultaneously, IR780 entered tumor cells under the influence of the LyP-1 peptide, and subsequently produced a substantial amount of ROS upon laser irradiation, leading to the death of tumor cells. Copper sulfide nanoparticles (CuS NPs), a commonly used photothermal material, can induce the polarization of TAMs towards M1 macrophages by increasing intracellular ROS levels. Therefore, Tong et al.166 developed an active targeted delivery system based on mesoporous sulfide CuS (IL@H-PP). The copper ions released by IL@H-PP induce an increase in ROS in TAMs, leading to their repolarization into an M1 phenotype. The light-triggered prodrug nanoparticles (LT-NPs) assembled from photosensitizers (Vitipofen), cathepsin B-specific clear peptide (FRRG), and doxorubicin can effectively stimulate the maturation of DCs and initiate anti-tumor immune responses167. MnO2@Ce6 nanoprobes-loaded-iPS cells (iPS-MnO2@Ce6) have been developed to enhance immunotherapy for cancer. Under illumination, iPS-MnO2@Ce6 promotes the maturation of DCs, thereby activating T cells and NK cells, and inducing immune responses168.

3.9.2 Nanomedicine-mediated ECM remodeling

ECM is a key factor in inducing tumor immune suppression. Targeting ECM can enhance immune cell infiltration and immune response. The abundant ECM in the TME acts as a physical barrier that prevents T cell infiltration169. In addition, ECM also participates in the polarization of TAMs. Reconstructing the ECM is crucial for promoting T-cell infiltration and polarizing TAMs toward an anti-tumor phenotype. Therefore, an increasing number of researchers are focusing on how to reconstruct the ECM170.

TGF-β can restrict T cell infiltration by inducing ECM deposition, which leads to the formation of TIME171. Therefore, Wang et al.172 utilized stimuli-responsive clustered nanoparticles (iCluster) for the hierarchical delivery of TGF-β receptor inhibitors (TGF-β Ri, LY2157299) and siRNA targeting the PD-L1 gene (LYiClustersiRNA). LYiClustersiRNA significantly increased the infiltration of CD8+ T cells and inhibited tumor growth. In recent years, studies have found that ECM is involved in regulating the phenotype of immune cells. For example, ECM can induce macrophages to exhibit an anti-tumor phenotype173. Therefore, future nanomedicines targeting ECM can be utilized to regulate the polarization of TAMs and contribute to anti-tumor immunity.

Compared to nanomedicines that specifically target one immune cell, nanomedicines that do not specifically target multiple immune cells may be a hot topic of future attention. Non-specific targeting of various immune cells can simultaneously regulate the anti-tumor response of multiple immune cells, as well as inhibit tumor growth and metastasis.

4 Conclusions, challenges, and future directions

As of now, chemotherapy remains the standard treatment for primary and metastatic cancer in clinical practice. It primarily induces cancer cell apoptosis or necrosis through the use of chemotherapy drugs174, 175, 176, 177. However, the occurrence of various adverse reactions and multidrug resistance poses a significant challenge for chemotherapy178, 179, 180. The emergence of cancer immunotherapy has opened up new avenues for chemotherapy. Unlike traditional chemotherapy, immunotherapy primarily stimulates the immune system to fight malignant tumors and prevent tumor recurrence181. Compared to chemotherapy drugs that directly kill cancer cells, immunotherapy has a lower rate of off-target effects. Immunotherapy is primarily regulated by a complex array of stimulating and inhibitory cell surface interactions. To ensure the effectiveness of immunotherapy, a series of immune cascade reactions must occur, including the expression or release of cancer antigens, antigen presentation, activation of immune cells, transport of immune cells, and their infiltration into the tumor, ultimately leading to the killing of cancer cells182. Conventional immunotherapy includes adoptive T cell therapy183,184, anticancer vaccination185,186, oncolytic viruses187,188, and ICIs189. Among these, ICIs represent a significant breakthrough in immunotherapy and are currently the primary focus of scientists. In cancer treatment, the two primary targets of ICIs are CTLA-4190,191 and PD-1/PD-L1192,193. CTLA-4, which is expressed in immune cells, was the first ICI approved by the U.S. Food and Drug Administration (FDA). It participates in the negative regulation of immune responses by binding to CD80 and CD86 ligands. The second-generation ICIs target PD-1 or its ligand PD-L1. PD-1 mainly regulates the function of T cells by binding to PD-L1 and PD-L2. Although ICIs have brought significant survival benefits to patients and have become a promising clinical treatment method. However, there are significant differences in tumor invasiveness, immune response, and prognosis among different types of cancers194. ICIs are not effective for most patients. The main reason for the limited clinical benefits is the inadequate or challenging infiltration of immune cells in the TME195,196. According to the type, quantity, and location of immune cells in the TME, tumors can be categorized as hot, altered-excluded, altered-immunosuppressed, and cold tumors197. The limited clinical benefits of chemotherapy and immunotherapy are attributed to the minimal infiltration of immune cells in cold tumors and the reduced infiltration of immune cells in altered-excluded and altered-immunosuppressed tumors198,199. Therefore, reprogramming these tumors to become “hot” tumors is a clear strategy for enhancing the clinical benefits of chemotherapy and immunotherapy200,201.

With the rapid advancement of nanotechnology, significant progress has been made in the field of cancer research. Research in the field of nanotechnology for cancer encompasses several directions: a) diagnosing and treating cancer202, 203, 204, b) regulating the TIME205, 206, 207, c) controlling drug release in the TME208,209, and d) reversing multidrug resistance210,211. The FDA has approved numerous nanoparticles, such as paclitaxel albumin-bound nanoparticles (Abraxane) and Onivydes, for clinical cancer treatment212,213. Nanotechnology has been proven to be an effective strategy for stimulating anti-tumor immunity214. The primary methods for nanotechnology to activate anti-tumor immunity involve regulating the function or infiltration of immune cells. Specifically, it mainly includes a) nanotechnology used to deliver immune cell function activators or inhibitors to regulate immune cell function215, and b) nanotechnology used as a drug delivery system to regulate TME and increase immune cell infiltration216, 217, 218. Due to the unsatisfactory efficacy of cancer treatment solely through the activation of anti-tumor immunity, nanotechnology is frequently employed in combination with chemotherapy drugs, ICIs, or PDTs219, 220, 221, 222. Nano drugs can penetrate more tumor sites and remain within tumors due to their unique size, allowing them to exert their effects more effectively223. In addition, because of the specific conditions in the TME (including hypoxia, weak acidity, and high GSH levels, etc.), nanomedicines designed to respond to the TME can accumulate more effectively at the intended sites, reducing potential damage to healthy organs224,225. Traditional immunotherapy can lead to the occurrence of immune-related adverse events (irAEs) during clinical translation due to nonspecific accumulation226. Compared to traditional immunotherapy, drugs or genes encapsulated in nanosystems can protect them from the influence of the internal environment. This strategy addresses the issue of short half-life and can extend the onset time of immunotherapy. Modifying the surface of nanomedicines can enable them to target immune cells more accurately and efficiently. As a result, the non-targeted issue of traditional immunotherapy has been resolved. Therefore, the introduction of nanotechnology represents a significant breakthrough in chemotherapy and immunotherapy.

While the integration of nanotechnology with chemotherapy and immunotherapy has yielded significant results, there are still unresolved issues that must be addressed before clinical application. a) The safety issues of nanomedicine227,228. In the field of cancer treatment, nanomedicines are primarily administered through intravenous or subcutaneous injection into the body. Understanding the distribution, metabolism, and excretion behavior of nanodrugs in vivo is essential for their development. After entering the body, 30%–99% of nanodrugs accumulate in the liver, leading to increased liver toxicity229, 230, 231. Polyethylene glycol-modified liposomes can induce immune responses and accelerate their clearance in the body232. Inorganic nanoparticles are difficult to degrade in the body, and long-term accumulation can affect bodily safety233. b) The side effects of immunotherapy. Immunotherapy may result in permanent neurological deficits and/or mortality234. Some immunotherapies can trigger irAEs, such as CTLA4 inhibition, which increases the incidence of pituitary inflammation235, and PD-L1 blockade, which increases the incidence of thyroid dysfunction236. Overcoming these challenges is crucial for the clinical advancement of nanotechnology-mediated immunotherapies. Therefore, future nanotechnology-mediated immunotherapy should focus on addressing its safety and side effects.

Acknowledgments

This work was supported by the 10.13039/501100001809 National Natural Science Foundation of China (82304853 ), 10.13039/501100009558 University Natural Science Research Project of Anhui Province (2022AH050533 , KJ2021A0586 , China), Chinese Society of Traditional Chinese Medicine Young Talent Support Project Program (CACM-2022-QNRC2-B03 ), and Anhui University of Traditional Chinese Medicine Talent Support Program (2022rczd004 ).

Author contributions

Yunna Chen: Writing – review & editing, Writing – original draft, Visualization. Qianqian Zhou: Writing – review & editing, Visualization. Zongfang Jia: Writing – review & editing. Nuo Cheng: Visualization. Sheng Zhang: Visualization. Weidong Chen: Writing – review & editing, Project administration. Lei Wang: Writing – review & editing, Project administration.

Conflicts of interest

The authors have no conflicts of interest to declare.

Appendix A Supporting information

The following is the Supporting information to this article:Multimedia component 1

Multimedia component 1

Peer review under the responsibility of Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences.

Appendix A Supporting information to this article can be found online at https://doi.org/10.1016/j.apsb.2024.05.032.
==== Refs
References

1 Riley R.S. June C.H. Langer R. Mitchell M.J. Delivery technologies for cancer immunotherapy Nat Rev Drug Discov 18 2019 175 196 30622344
2 Zhang Y.Y. Zhang Z.M. The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications Cell Mol Immunol 17 2020 807 821 32612154
3 Dagher O.K. Schwab R.D. Brookens S.K. Posey A.D. Advances in cancer immunotherapies Cell 186 2023 1814 1815 37059073
4 Han Y.Y. Liu D.D. Li L.H. PD-1/PD-L1 pathway: current researches in cancer Am J Cancer Res 10 2020 727 742 32266087
5 Ma Y.X. Xue J.H. Zhao Y.Y. Zhang Y. Huang Y. Yang Y.P. Phase I trial of KN046, a novel bispecific antibody targeting PD-L1 and CTLA-4 in patients with advanced solid tumors J Immunother Cancer 11 2023 e006654
6 Gao X.Y. Xu N. Li Z.Y. Shen L. Ji K. Zheng Z. Safety and antitumour activity of cadonilimab, an anti-PD-1/CTLA-4 bispecific antibody, for patients with advanced solid tumours (COMPASSION-03): a multicentre, open-label, phase 1b/2 trial Lancet Oncol 24 2023 1134 1146 37797632
7 Wolchok J.D. Kluger H. Callahan M.K. Postow M.A. Rizvi N.A. Lesokhin A.M. Nivolumab plus Ipilimumab in advanced melanoma New Engl J Med 369 2013 122 133 23724867
8 Nakamura K. Smyth M.J. Myeloid immunosuppression and immune checkpoints in the tumor microenvironment Cel Mol Immunol 17 2020 1 12
9 Li L.H. Yu R. Cai T.G. Chen Z. Lan M. Zou T.T. Effects of immune cells and cytokines on inflammation and immunosuppression in the tumor microenvironment Int Immunopharmacol 88 2020 106939
10 Shafqat A. Omer M.H. Ahmed E.N. Mushtaq A. Ijaz E. Ahmed Z. Reprogramming the immunosuppressive tumor microenvironment: exploiting angiogenesis and thrombosis to enhance immunotherapy Front Immunol 14 2023 1200941
11 Fan D.H. Cao Y.K. Cao M.Q. Wang Y.J. Cao Y.L. Gong T. Nanomedicine in cancer therapy Signal Transduct Tar 8 2023 293
12 Xu M.M. Han X.P. Xiong H.T. Gao Y.J. Xu B.W. Zhu G.H. Cancer nanomedicine: emerging strategies and therapeutic potentials Molecules 28 2023 5145 37446806
13 Gawali P. Saraswat A. Bhide S. Gupta S. Patel K. Human solid and clinical relevance of the enhanced permeation and retention effect: a 'golden gate' for nanomedicine in preclinical studies? Nanomedicine-Uk 18 2023 169 190
14 Zhang M. Ma H. Wang X.J. Yu B. Cong H.L. Shen Y.Q. Polysaccharide-based nanocarriers for efficient transvascular drug delivery J Control Release 354 2023 167 187 36581260
15 Shi Y. Van der Meel R. Chen X.Y. Lammers T. The EPR effect and beyond: strategies to improve tumor targeting and cancer nanomedicine treatment efficacy Theranostics 10 2020 7921 7924 32685029
16 Martin J.D. Cabral H. Stylianopoulos T. Jain R.K. Improving cancer immunotherapy using nanomedicines: progress, opportunities and challenges Nat Rev Clin Oncol 17 2020 251 266 32034288
17 Cheng R.Y. Santos H.A. Smart nanoparticle-based platforms for regulating tumor microenvironment and cancer immunotherapy Adv Healthc Mater 12 2022 e2202063
18 Jia M. Zhang D. Zhang C.X. Li C.H. Nanoparticle-based delivery systems modulate the tumor microenvironment in pancreatic cancer for enhanced therapy J Nanobiotechnol 19 2021 384
19 Xu Y.Y. Xiong J.Y. Sun X.Y. Gao H.L. Targeted nanomedicines remodeling immunosuppressive tumor microenvironment for enhanced cancer immunotherapy Acta Pharm Sin B 12 2022 4327 4347 36561994
20 Gu Z.Y. Liu T.Q. Liu C. Yang Y.N. Tang J. Song H. Ferroptosis-strengthened metabolic and inflammatory regulation of tumor-associated macrophages provokes potent tumoricidal activities Nano Lett 21 2021 6471 6479 34292757
21 Ma X. Yang S. Zhang T. Wang S. Yang Q. Xiao Y. Bioresponsive immune-booster-based prodrug nanogel for cancer immunotherapy Acta Pharm Sin B 12 2022 451 466 35127398
22 Lv B.Z. Wang Y.P. Ma D.J. Cheng W. Liu J. Yong T. Immunotherapy: reshape the tumor immune microenvironment Front Immunol 13 2022 844142
23 Grout J.A. Sirven P. Leader A.M. Maskey S. Hector E. Puisieux I. Spatial positioning and matrix programs of cancer-associated fibroblasts promote T-cell exclusion in human lung tumor Cancer Discov 12 2022 2606 2625 36027053
24 Ugel S. Canè S. De Sanctis F. Bronte V. Monocytes in the tumor microenvironment Annu Rev Pathol-mech 16 2021 93 122
25 Elanany M.M. Mostafa D. Hamdy N.M. Remodeled tumor immune microenvironment (TIME) parade natural killer cells reprogramming in breast cancer Life Sci 330 2023 121997
26 Wang X.X. Zha H.R. Wu W. Yuan T. Xie S.L. Jin Z. CD200+ cytotoxic T lymphocytes in the tumor microenvironment are crucial for efficacious anti-PD-1/PD-L1 therapy Sci Transl Med 15 2023 eabn5029
27 Friedrich M. Hahn M. Michel J. Sankowski R. Kilian M. Kehl N. Dysfunctional dendritic cells limit antigen-specific T cell response in glioma Neuro Oncol 25 2023 263 276 35609569
28 Terrén I. Orrantia A. Vitallé J. Zenarruzabeitia O. Borrego F. NK cell metabolism and tumor microenvironment Front Immunol 10 2019 2278 31616440
29 Chen C. Wang Z.H. Ding Y. Qin Y.R. Tumor microenvironment-mediated immune evasion in hepatocellular carcinoma Front Immunol 14 2023 1133308
30 Sathe A. Mason K. Grimes S.M. Zhou Z.L. Lau B.T. Bai X.Q. Colorectal cancer metastases in the liver establish immunosuppressive spatial networking between tumor-associated macrophages and fibroblasts Clin Cancer Res 29 2023 244 260 36239989
31 Bonaventura P. Shekarian T. Alcazer V. Valladeau-Guilemond J. Valsesia-Wittmann S. Amigorena S. Cold tumors: a therapeutic challenge for immunotherapy Front Immunol 10 2019 168 30800125
32 Zhang B.X. Hu M. Ma Q.Z. Li K. Li X. He X. Optimized CAR-T therapy based on spatiotemporal changes and chemotactic mechanisms of MDSCs induced by hypofractionated radiotherapy Mol Ther 31 2023 2105 2119 37073129
33 Wang B.Y. Zhang Z.B. Liu W.B. Tan B.B. Targeting regulatory T cells in gastric cancer: pathogenesis, immunotherapy, and prognosis Biomed Pharmacother 158 2023 114180
34 Chen Y.J. Li G.N. Li X.J. Wei L.X. Fu M.J. Cheng Z.L. Targeting IRG1 reverses the immunosuppressive function of tumor-associated macrophages and enhances cancer immunotherapy Sci Adv 9 2023 eadg0654
35 Nixon B.G. Kuo F.S. Ji L.L. Liu M. Capistrano K. Do M. Tumor-associated macrophages expressing the transcription factor IRF8 promote T cell exhaustion in cancer Immunity 55 2022 2044 2058 36288724
36 Mao X.Q. Xu J. Wang W. Liang C. Hua J. Liu J. Crosstalk between cancer-associated fibroblasts and immune cells in the tumor microenvironment: new findings and future perspectives Mol Cancer 20 2021 131 34635121
37 Liu C. Chikina M. Deshpande R. Menk A.V. Wang T. Tabib T. Treg cells promote the SREBP1-dependent metabolic fitness of tumor-promoting macrophages via repression of CD8+ T cell-derived interferon-γ Immunity 51 2019 381 397 31350177
38 Zalfa C. Paust S. Natural killer cell interactions with myeloid derived suppressor cells in the tumor microenvironment and implications for cancer immunotherapy Front Immunol 12 2021 633205
39 Liu L. Zhou X.L. Cheng S. Ge Y.Y. Chen B.M. Shi J. RNA-binding protein DHX9 promotes glioma growth and tumor-associated macrophages infiltration via TCF12 Cns Neurosci Ther 29 2023 988 999 36377508
40 Kawaguchi Y. Ohshio Y. Watanabe A. Shiratori T. Okamoto K. Ueda K. Depletion of tumor-associated macrophages inhibits lung cancer growth and enhances the antitumor effect of cisplatin Cancer Sci 114 2023 750 763 36411518
41 Rohila D. Park I.H. Pham T.V. Weitz J. de Mendoza T.H. Madheswaran S. Syk inhibition reprograms tumor-associated macrophages and overcomes gemcitabine-induced immunosuppression in pancreatic ductal adenocarcinoma Cancer Res 83 2023 2675 2689 37306759
42 Liu J.F. Xiang J.X. Jin C.Y. Ye L.S. Wang L. Gao Y.A. Medicinal plant-derived mtDNA via nanovesicles induces the cGAS-STING pathway to remold tumor-associated macrophages for tumor regression J Nanobiotechnol 21 2023 78
43 Fathi N. Mojtahedi H. Nasiri M. Abolhassani H. Marzbali M.Y. Esmaeili M. How do nuclear factor kappa B (NF-κB)1 and NF-κB2 defects lead to the incidence of clinical and immunological manifestations of inborn errors of immunity? Expert Rev Clin Immu 19 2023 329 339
44 He Z.W. Wang J. Zhu C.H. Xu J. Chen P. Jiang X.Y. Exosome-derived FGD5-AS1 promotes tumor-associated macrophage M2 polarization-mediated pancreatic cancer cell proliferation and metastasis Cancer Lett 548 2022 215751
45 Zhao T. Zeng J.M. Xu Y.J. Su Z.P. Chong Y.L. Ling T. Chitinase-3 like-protein-1 promotes glioma progression via the NF-κB signaling pathway and tumor microenvironment reprogramming Theranostics 12 2022 6989 7008 36276655
46 Li G.L. Tang J.F. Tan W.L. Zhang T. Zeng D. Zhao S. The anti-hepatocellular carcinoma effects of polysaccharides from Ganoderma lucidum by regulating macrophage polarization via the MAPK/NF-κB signaling pathway Food Funct 14 2023 3155 3168 36883482
47 Mishima K. Nishikawa R. Narita Y. Mizusawa J. Sumi M. Koga T. Randomized phase III study of high-dose methotrexate and whole-brain radiotherapy with/without temozolomide for newly diagnosed primary CNS lymphoma: JCOG1114C Neuro Oncol 25 2023 687 698 36334050
48 Bharadwaj R. Lusi C.F. Mashayekh S. Nagar A. Subbarao M. Kane G.I. Methotrexate suppresses psoriatic skin inflammation by inhibiting muropeptide transporter SLC46A2 activity Immunity 56 2023 998 1012 37116499
49 Cavalcante R.M.S. Ishikawa U. Silva E.S. Silva A.A. Araújo A.A. Cruz L.J. STAT3/NF-κB signalling disruption in M2 tumour-associated macrophages is a major target of PLGA nanocarriers/PD-L1 antibody immunomodulatory therapy in breast cancer Br J Pharmacol 178 2021 2284 2304 33434950
50 Li K. Lu L. Xue C.C. Liu J. He Y. Zhou J. Polarization of tumor-associated macrophage phenotype porous hollow iron nanoparticles for tumor immunotherapy in vivo Nanoscale 12 2020 130 144 31799577
51 Liu Y. Liang S. Jiang D.D. Gao T. Fang Y.X. Fu S.L. Manipulation of TAMs functions to facilitate the immune therapy effects of immune checkpoint antibodies J Control Release 336 2021 621 634 34246701
52 Yang L.N. Sun J. Liu Q. Zhu R.R. Yang Q.N. Hua J.H. Synergetic functional nanocomposites enhance immunotherapy in solid tumors by remodeling the immunoenvironment Adv Sci 6 2019 1802012
53 Saxton R.A. Glassman C.R. Garcia K.C. Emerging principles of cytokine pharmacology and therapeutics Nat Rev Drug Discov 22 2023 21 37 36131080
54 Li X.Y. Liu M. Fu Y.J. Jiang Y.J. Zhang Z.N. Alterations in levels of cytokine following treatment to predict outcome of sepsis: a meta-analysis Cytokine 161 2023 156056
55 Bhatia V. Kamat N.V. Pariva T.E. Wu L.T. Tsao A. Sasaki K. Targeting advanced prostate cancer with STEAP1 chimeric antigen receptor T cell and tumor-localized IL-12 immunotherapy Nat Commun 14 2023 2041 37041154
56 Qiu N.S. Wang G.W. Wang J.Q. Zhou Q. Guo M.Y. Wang Y.L. Tumor-associated macrophage and tumor-cell dually transfecting polyplexes for efficient interleukin-12 cancer gene therapy Adv Mater 33 2021 e2006189
57 Wan Y.F. Yu W.J. Li J.M. Peng N. Ding X. Wang Y.L. Multi-functional carboxymethyl chitin-based nanoparticles for modulation of tumor-associated macrophage polarity Carbohyd Polym 267 2021 118245
58 Li T.S. Liu Z.H. Fu X. Chen Y.Q. Zhu S.L. Zhang J. Co-delivery of interleukin-12 and doxorubicin loaded nano-delivery system for enhanced immunotherapy with polarization toward M1-type macrophages Eur J Pharm Biopharm 177 2022 175 183 35811038
59 Sun Y. Cronin M.F. Mendonça M.C.P. Guo J.F. O'Driscoll C.M. Sialic acid-targeted cyclodextrin-based nanoparticles deliver siRNA and reprogram tumour-associated macrophages for immunotherapy of prostate cancer Eur J Pharm Sci 185 2023 106427
60 Li Y. Yang B. Miao H.J. Liu L.G. Wang Z.Y. Jiang C.K. Nicotinamide-methyltransferase promotes M2 macrophage polarization by IL6 and MDSC conversion by GM-CSF in gallbladder carcinoma Hepatology 78 2023 1352 1367 36633260
61 Sun Y. Cronin M.F. Mendonça M.C.P. Guo J.F. O'Driscoll C.M. M2pep-modified cyclodextrin-siRNA nanoparticles modulate the immunosuppressive tumor microenvironment for prostate cancer therapy Mol Pharmaceut 20 2023 5921 5936
62 Magkouta S.F. Vaitsi P.C. Pappas A.G. Iliopoulou M. Kosti C.N. Psarra K. CSF1/CSF1R axis blockade limits mesothelioma and enhances efficiency of anti-PDL1 immunotherapy Cancers 13 2021 2546 34067348
63 Ramesh A. Brouillard A. Kumar S. Nandi D. Kulkarni A. Dual inhibition of CSF1R and MAPK pathways using supramolecular nanoparticles enhances macrophage immunotherapy Biomaterials 227 2020 119559
64 Xiong H.Z. Mittman S. Rodriguez R. Moskalenko M. Pacheco-Sanchez P. Yang Y.G. Anti-PD-L1 treatment results in functional remodeling of the macrophage compartment Cancer Res 79 2019 1493 1506 30679180
65 Ramesh A. Malik V. Ranjani H.A. Smith H. Kulkarni A.A. Rational combination of an immune checkpoint inhibitor with CSF1R inhibitor-loaded nanoparticle enhances anticancer efficacy Drug Deliv Transl Re 11 2021 2317 2327
66 Han Y.C. Sun J.C. Yang Y.Y. Liu Y.L. Lou J. Pan H.M. TMP195 exerts antitumor effects on colorectal cancer by promoting M1 macrophages polarization Int J Biol Sci 18 2022 5653 5666 36263186
67 Yue Y.L. Li F.F. Li Y. Wang Y.Z. Guo X.J. Cheng Z.X. Biomimetic nanoparticles carrying a repolarization agent of tumor-associated macrophages for remodeling of the inflammatory microenvironment following photothermal therapy Acs Nano 15 2021 15166 15179 34469109
68 Figueiredo P. Lepland A. Scodeller P. Fontana F. Torrieri G. Tiboni M. Peptide-guided resiquimod-loaded lignin nanoparticles convert tumor-associated macrophages from M2 to M1 phenotype for enhanced chemotherapy Acta Biomater 133 2021 231 243 33011297
69 Costa da Silva M. Breckwoldt M.O. Vinchi F. Correia M.P. Stojanovic A. Thielmann C.M. Iron induces anti-tumor activity in tumor-associcated macrophages Front Immunol 8 2017 1479 29167669
70 Zhao M. Li J. Liu J.W. Xu M.X. Ji H.R. Wu S.W. Charge-switchable nanoparticles enhance cancer immunotherapy based on mitochondrial dynamic regulation and immunogenic cell death induction J Control Release 335 2021 320 332 34062192
71 Yang L.N. Li F. Cao Y.S. Liu Q. Jing G.X. Niu J.T. Multifunctional silica nanocomposites prime tumoricidal immunity for efficient cancer immunotherapy J Nanobiotechnol 19 2021 328
72 Zeng W.W. Yu M. Chen T. Liu Y.Q. Yi Y.F. Huang C.Y. Polypyrrole nanoenzymes as tumor microenvironment modulators to reprogram macrophage and potentiate immunotherapy Adv Sci 9 2022 2201703
73 Yu Y.K. Li T.X. Ou M.T. Luo R. Chen H.Z. Ren H. OX40L-expressing M1-like macrophage exosomes for cancer immunotherapy J Control Release 365 2024 469 479 38040340
74 Zhao Q.N. Hu J.M. Kong L.Y. Jiang S. Tian X.J. Wang J. FGL2-targeting T cells exhibit antitumor effects on glioblastoma and recruit tumor-specific brain-resident memory T cells Nat Commun 14 2023 735 36759517
75 Cui Y.B. Yuan T.J. Wang Y. Zheng D.W. Qin L. Li S.L. T lymphocytes expressing the switchable chimeric Fc receptor CD64 exhibit augmented persistence and antitumor activity Cell Rep 42 2023 112797
76 Park J. Hsueh P.C. Li Z.Y. Ho P.C. Microenvironment-driven metabolic adaptations guiding CD8+ T cell anti-tumor immunity Immunity 56 2023 32 42 36630916
77 Wang Y.X. Wang W.R. Gu R. Chen J. Chen Q. Lin T.S. In situ vaccination with mitochondria-targeting immunogenic death inducer elicits CD8 T cell-dependent antitumor immunity to boost tumor immunotherapy Adv Sci 10 2023 e2300286
78 Brightman S.E. Becker A. Thota R.R. Naradikian M.S. Chihab L. Zavala K.S. Neoantigen-specific stem cell memory-like CD4 T cells mediate CD8 T cell-dependent immunotherapy of MHC class II-negative solid tumors Nat Immunol 24 2023 1345 1357 37400675
79 Protti M.P. Monte L.D. Lullo G.D. Tumor antigen-specific CD4+ T cells in cancer immunity: from antigen identification to tumor prognosis and development of therapeutic strategies Tissue Antigens 83 2014 237 246 24641502
80 Cheng J. Yan J.X. Liu Y. Shi J.Z. Wang H.Y. Zhou H.Y. Cancer-cell-derived fumarate suppresses the anti-tumor capacity of CD8+ T cells in the tumor microenvironment Cell Metab 35 2023 961 978 37178684
81 Hu C. Song Y.J. Zhang Y.W. He S.Q. Liu X.Y. Yang X.T. Sequential delivery of PD-1/PD-L1 blockade peptide and IDO inhibitor for immunosuppressive microenvironment remodeling via an MMP-2 responsive dual-targeting liposome Acta Pharm Sin B 13 2023 2176 2187 37250156
82 Lester D.K. Burton C. Gardner A. Innamarato P. Kodumudi K. Liu Q. Fucosylation of HLA-DRB1 regulates CD4+ T cell-mediated anti-melanoma immunity and enhances immunotherapy efficacy Nat Cancer 4 2023 222 239 36690875
83 Trefny M.P. Kirchhammer N. Auf der Maur P. Natoli M. Schmid D. Germann M. Deletion of alleviates CD8 T cell exhaustion for effective cellular cancer immunotherapy Nat Commun 14 2023 86 36732507
84 Lin Y.X. Wang Y. Ding J.X. Jiang A.P. Wang J. Yu M.A. Reactivation of the tumor suppressor PTEN by mRNA nanoparticles enhances antitumor immunity in preclinical models Sci Transl Med 13 2021 eaba9772
85 Lukhele S. Abd Rabbo D. Guo M.D. Shen J. Elsaesser H.J. Quevedo R. The transcription factor IRF2 drives interferon-mediated CD8+ T cell exhaustion to restrict anti-tumor immunity Immunity 55 2022 2369 2385 36370712
86 Wang T.T. Zhang H. Han Y.B. Zheng Q. Liu H.H. Han M.X. Reversing T cell dysfunction to boost glioblastoma immunotherapy by paroxetine-mediated GRK2 inhibition and blockade of multiple checkpoints through biomimetic nanoparticles Adv Sci 10 2023 e2204961
87 Ren H. Yong J.H. Yang Q.Q. Yang Z. Liu Z.Y. Xu Y. Self-assembled FeS-based cascade bioreactor with enhanced tumor penetration and synergistic treatments to trigger robust cancer immunotherapy Acta Pharm Sin B 11 2021 3244 3261 34729313
88 Chen Q. Hu Q.Y. Dukhovlinova E. Chen G.J. Ahn S. Wang C. Photothermal therapy promotes tumor infiltration and antitumor activity of CAR T cells Adv Mater 31 2019 e1900192
89 Sanmarco L.M. Rone J.M. Polonio C.M. Lahore G.F. Giovannoni F. Ferrara K. Lactate limits CNS autoimmunity by stabilizing HIF-1α in dendritic cells Nature 620 2023 881 889 37558878
90 Zhao J.L. Tian Z.M. Zhao S.J. Feng D.Y. Guo Z.X. Wen L.Z. Insights into the effect of catalytic intratumoral lactate depletion on metabolic reprogramming and immune activation for antitumoral activity Adv Sci 10 2023 e2204808
91 Wang J.X. Choi S.Y.C. Niu X.J. Kang N. Xue H. Killam J. Lactic acid and an acidic tumor microenvironment suppress anticancer immunity Int J Mol Sci 21 2020 8363 33171818
92 Gaggero S. Martinez-Fabregas J. Cozzani A. Fyfe P.K. Leprohon M. Yang J. IL-2 is inactivated by the acidic pH environment of tumors enabling engineering of a pH-selective mutein Sci Immunol 7 2022 eade5686
93 Fang Y. Liu W.R. Tang Z. Ji X. Zhou Y.F. Song S.S. Monocarboxylate transporter 4 inhibition potentiates hepatocellular carcinoma immunotherapy through enhancing T cell infiltration and immune attack Hepatology 77 2023 109 123 35043976
94 Shi P.F. Sun X.R. Yuan H.M. Chen K.X. Bi S. Zhang S.S. Nanoscale metal-organic frameworks combined with metal nanoparticles and metal oxide/peroxide to relieve tumor hypoxia for enhanced photodynamic therapy Acs Biomater Sci Eng 9 2023 5441 5456 37729521
95 Zhang Y.X. Zhao Y.Y. Shen J.Z. Sun X. Liu Y. Liu H. Nanoenabled modulation of acidic tumor microenvironment reverses anergy of infiltrating T cells and potentiates anti-PD-1 therapy Nano Lett 19 2019 2774 2783 30943039
96 Lu Y. Li L.H. Du J.W. Chen J.L. Xu X.Y. Yang X.F. Immunotherapy for tumor metastasis by artificial antigen-presenting cells via targeted microenvironment regulation and T-cell activation Acs Appl Mater Inter 13 2021 55890 55901
97 Tay C. Tanaka A. Sakaguchi S. Tumor-infiltrating regulatory T cells as targets of cancer immunotherapy Cancer Cell 41 2023 450 465 36917950
98 Kumar P. Bhattacharya P. Prabhakar B.S. A comprehensive review on the role of co-signaling receptors and Treg homeostasis in autoimmunity and tumor immunity J Autoimmun 95 2018 77 99 30174217
99 Eggenhuizen P.J. Ng B.H. Ooi J.D. Treg enhancing therapies to treat autoimmune diseases Int J Mol Sci 21 2020 7015 32977677
100 van Hooren L. Handgraaf S.M. Kloosterman D.J. Karimi E. van Mil L.W.H.G. Gassama A.A. CD103 regulatory T cells underlie resistance to radio-immunotherapy and impair CD8 T cell activation in glioblastoma Nat Cancer 4 2023 665 681 37081259
101 So L. Obata-Ninomiya K. Hu A. Muir V.S. Takamori A. Song J. Regulatory T cells suppress CD4 effector T cell activation by controlling protein synthesis J Exp Med 220 2023 e20221676
102 Domvri K. Petanidis S. Zarogoulidis P. Anestakis D. Tsavlis D. Bai C. Treg-dependent immunosuppression triggers effector T cell dysfunction via the STING/ILC2 axis Clin Immunol 222 2021 108620
103 Kurniawan H. Franchina D.G. Guerra L. Bonetti L. Soriano-Baguet L. Grusdat M. Glutathione restricts serine metabolism to preserve regulatory T cell function Cel Metab 31 2020 920 936
104 Suthen S. Lim C.J. Nguyen P.H.D. Dutertre C.A. Lai H.L.H. Wasser M. Hypoxia-driven immunosuppression by Treg and type-2 conventional dendritic cells in HCC Hepatology 76 2022 1329 1344 35184329
105 Zhang Y.L. Chai N. Wei Z.Z. Li Z. Zhang L. Zhang M.J. YYFZBJS inhibits colorectal tumorigenesis by enhancing Tregs-induced immunosuppression through HIF-1α mediated hypoxia in vivo and in vitro Phytomedicine 98 2022 153917
106 Li Z.T. Deng Y.Y. Sun H.H. Tan C.X. Li H.M. Mo F.Y. Redox modulation with a perfluorocarbon nanoparticle to reverse Treg-mediated immunosuppression and enhance anti-tumor immunity J Control Release 358 2023 579 590 37172908
107 Ou W. Thapa R.K. Jiang L.Y. Soe Z.C. Gautam M. Chang J.H. Regulatory T cell-targeted hybrid nanoparticles combined with immuno-checkpoint blockage for cancer immunotherapy J Control Release 281 2018 84 96 29777794
108 He S.Q. Wang L.L. Wu D.X. Tong F. Zhao H. Li H.M. Dual-responsive supramolecular photodynamic nanomedicine with activatable immunomodulation for enhanced antitumor therapy Acta Pharm Sin B 14 2024 765 780 38322349
109 Ou W. Jiang L. Thapa R.K. Soe Z.C. Poudel K. Chang J.H. Combination of NIR therapy and regulatory T cell modulation using layer-by-layer hybrid nanoparticles for effective cancer photoimmunotherapy Theranostics 8 2018 4574 4590 30279723
110 Hossain D.M.S. Panda A.K. Chakrabarty S. Bhattacharjee P. Kajal K. Mohanty S. MEK inhibition prevents tumour-shed transforming growth factor-β-induced T-regulatory cell augmentation in tumour milieu Immunology 144 2015 561 573 25284464
111 Zhang N. Liu S.N. Shi S.Y. Chen Y.T. Xu F.W. Wei X.H. Solubilization and delivery of Ursolic-acid for modulating tumor microenvironment and regulatory T cell activities in cancer immunotherapy J Control Release 320 2020 168 178 31926193
112 Das A. Tsai H.C. Sen T. Moirangthem R.S. Plasmonic nanoparticle-based surface-enhanced Raman spectroscopy-guided photothermal therapy: emerging cancer theranostics Nanomedicine-Uk 18 2023 555 576
113 Chen Z.Y. Chen Y.C. Xu Y.J. Shi X.C. Han Z. Bai Y. BODIPY-based multifunctional nanoparticles for dual mode imaging-guided tumor photothermal and photodynamic therapy ACS Appl Bio Mater 18 2023 3406 3413
114 Deng C.T. Zheng M.C. Xin J.Q. An F.F. A nanoparticle composed of totally hospital-available drugs and isotope for fluorescence/SPECT dual-modal imaging-guided photothermal therapy to inhibit tumor metastasis J Colloid Interf Sci 651 2023 384 393
115 Chen H.W. Luan X. Paholak H.J. Burnett J.P. Stevers N.O. Sansanaphongpricha K. Depleting tumor-associated Tregs via nanoparticle-mediated hyperthermia to enhance anti-CTLA-4 immunotherapy Nanomedicine-Uk 15 2020 77 92
116 Bednar K.J. Lee J.H. Ort T. Tregs in autoimmunity: insights into intrinsic brake mechanism driving pathogenesis and immune homeostasis Front Immunol 13 2022 932485
117 Sakaguchi S. Naturally arising CD4+ regulatory t cells for immunologic self-tolerance and negative control of immune responses Annu Rev Immunol 22 2004 531 562 15032588
118 Maj T. Wang W. Crespo J. Zhang H.J. Wang W.M. Wei S. Oxidative stress controls regulatory T cell apoptosis and suppressor activity and PD-L1-blockade resistance in tumor Nat Immunol 18 2017 1332 1341 29083399
119 Yan R. Li J.J. Xiao Z.R. Fan X.A. Liu H.S. Xu Y. DCLK1 suppresses tumor-specific cytotoxic T lymphocyte function through recruitment of MDSCs via the CXCL1-CXCR2 axis Cell Mol Gastroenter 15 2023 463 485
120 Giannotta C. Autino F. Massaia M. The immune suppressive tumor microenvironment in multiple myeloma: the contribution of myeloid-derived suppressor cells Front Immunol 13 2023 1102471
121 Liu H.Y. Wang Z.C. Zhou Y.T. Yang Y.M. MDSCs in breast cancer: an important enabler of tumor progression and an emerging therapeutic target Front Immunol 14 2023 1199273
122 Dai X.H. Ren L. Liu M.X. Cai H. Zhang H. Gong Q.Y. Nanomedicines modulating myeloid-derived suppressor cells for improving cancer immunotherapy Nano Today 39 2021 101163
123 Plebanek M.P. Bhaumik D. Bryce P.J. Thaxton C.S. Scavenger receptor type B1 and lipoprotein nanoparticle inhibit myeloid-derived suppressor cells Mol Cancer Ther 17 2018 686 697 29282300
124 Zhang T. Xiong H.G. Ma X.B. Gao Y. Xue P. Kang Y.J. Supramolecular tadalafil nanovaccine for cancer immunotherapy by alleviating myeloid-derived suppressor cells and heightening immunogenicity Small Methods 5 2021 e2100115
125 Chiu D.K.C. Xu I.M.J. Lai R.K.H. Tse A.P.W. Wei L.L. Koh H.Y. Hypoxia induces myeloid-derived suppressor cell recruitment to hepatocellular carcinoma through chemokine (C-C motif) ligand 26 Hepatology 64 2016 797 813 27228567
126 Zuo H.Q. Hou Y.C. Yu Y.J. Li Z.Q. Liu H.X. Liu C. Circumventing myeloid-derived suppressor cell-mediated immunosuppression using an oxygen-generated and -economized nanoplatform Acs Appl Mater Inter 12 2020 55723 55736
127 Xia C.Y. Li M. Ran G.Y. Wang X.H. Lu Z.Z. Li T. Redox-responsive nanoassembly restrained myeloid-derived suppressor cells recruitment through autophagy-involved lactate dehydrogenase a silencing for enhanced cancer immunochemotherapy J Control Release 335 2021 557 574 34051289
128 Lu G.F. Du R. Dong J.Q. Sun Y. Zhou F.L. Feng F. Cancer associated fibroblast derived SLIT2 drives gastric cancer cell metastasis by activating NEK9 Cell Death Dis 14 2023 421 37443302
129 Zhao Z.X. Zhang Y.Q. Guo E.R. Zhang Y. Wang Y.N. Periostin secreted from podoplanin-positive cancer-associated fibroblasts promotes metastasis of gastric cancer by regulating cancer stem cells via AKT and YAP signaling pathway Mol Carcinogen 62 2023 685 699
130 Jenkins L. Jungwirth U. Avgustinova A. Iravani M. Mills A. Haider S. Cancer-associated fibroblasts suppress CD8+ T-cell infiltration and confer resistance to immune-checkpoint blockade Cancer Res 82 2022 2904 2917 35749591
131 Zhu G.Q. Tang Z. Huang R. Qu W.F. Fang Y. Yang R. CD36 cancer-associated fibroblasts provide immunosuppressive microenvironment for hepatocellular carcinoma via secretion of macrophage migration inhibitory factor Cell Discov 9 2023 25 36878933
132 Ai W. Liu T.H. Lv C.S. Feng X.R. Wang Q.S. Modulation of cancer-associated fibroblasts by nanodelivery system to enhance efficacy of tumor therapy Nanomedicine-Uk 18 2023 1025 1039
133 Fei B.Y. Mo Z.H. Yang J.H. Wang Z. Li S. Nanodrugs reprogram cancer-associated fibroblasts and normalize tumor vasculatures for sequentially enhancing photodynamic therapy of hepatocellular carcinoma Int J Nanomed 18 2023 6379 6391
134 Zhang H.Y. Chen L.Y. Zhao Y. Luo N.C. Shi J.B. Xu S.J. Relaxin-encapsulated polymeric metformin nanoparticles remodel tumor immune microenvironment by reducing CAFs for efficient triple-negative breast cancer immunotherapy Asian J Pharm Sci 18 2023 100796
135 He Y. Wu S.Y. Yuan Y.B. Sun Y.C. Ai Q.J. Zhou R.Q. Remodeling tumor immunosuppression with molecularly imprinted nanoparticles to enhance immunogenic cell death for cancer immunotherapy J Control Release 362 2023 44 57 37579978
136 Huang M.Y. Chen Y.C. Lyu W.Y. He X.Y. Ye Z.H. Huang C.Y. Ginsenoside Rh2 augmented anti-PD-L1 immunotherapy by reinvigorating CD8+ T cells via increasing intratumoral CXCL10 Pharmacol Res 198 2023 106988
137 Man S.L. Yao J.W. Lv P.P. Liu Y. Yang L. Ma L. Curcumin-enhanced antitumor effects of sorafenib regulating the metabolism and tumor microenvironment Food Funct 11 2020 6422 6432 32613952
138 Racz L.Z. Racz C.P. Pop L.C. Tomoaia G. Mocanu A. Barbu I. Strategies for improving bioavailability, bioactivity, and physical-chemical behavior of curcumin Molecules 27 2022 6854 36296447
139 Chang R.X. Chen L.R. Qamar M. Wen Y.J. Li L.Z. Zhang J.Y. The bioavailability, metabolism and microbial modulation of curcumin-loaded nanodelivery systems Adv Colloid Interfac 318 2023 102933
140 Zheng F. Luo Y.J. Liu Y.Q. Gao Y.Y. Chen W.Y. Wei K. Nano-baicalein facilitates chemotherapy in breast cancer by targeting tumor microenvironment Int J Pharmaceut 635 2023 122778
141 Chen Y.N. Hu M.R. Wang S.W. Wang Q. Lu H.Y. Wang F. Nano-delivery of salvianolic acid B induces the quiescence of tumor-associated fibroblasts via interfering with TGF-β1/Smad signaling to facilitate chemo- and immunotherapy in desmoplastic tumor Int J Pharm 623 2022 121953
142 Pan J.X. Lai Y. Zhang S.A. Zhang H.J. Shan Y.M. Huang L.J. Self-adaptive nanoregulator to mitigate dynamic immune evasion of pancreatic cancer Adv Mater 35 2023 e2305798
143 Zang S.Y. Huang K.X. Li J.X. Ren K.B. Li T. He X. Metabolic reprogramming by dual-targeting biomimetic nanoparticles for enhanced tumor chemo-immunotherapy Acta Biomater 148 2022 181 193 35649505
144 Vivier E. Rebuffet L. Narni-Mancinelli E. Cornen S. Igarashi R.Y. Fantin V.R. Natural killer cell therapies Nature 626 2024 727 736 38383621
145 Li L.F. Li A. Jin H. Li M.Y. Jia Q.G. Inhibitory receptors and checkpoints on NK cells: implications for cancer immunotherapy Pathol Res Pract 253 2024 155003
146 Zheng W. Ling S.K. Cao Y.D. Shao C.L. Sun X.C. Combined use of NK cells and radiotherapy in the treatment of solid tumors Front Immunol 14 2024 1306534
147 Sun X.S. Xu X.X. Wang J. Zhang X.Y. Zhao Z.T. Liu X.C. Acid-switchable nanoparticles induce self-adaptive aggregation for enhancing antitumor immunity of natural killer cells Acta Pharm Sin B 13 2023 3093 3105 37521862
148 Lian G.Y. Wan Y. Mak T.S. Wang Q.M. Zhang J. Chen J. Self-carried nanodrug (SCND-SIS3): a targeted therapy for lung cancer with superior biocompatibility and immune boosting effects Biomaterials 288 2022 121730
149 Nakamura T. Sasaki S. Sato Y. Harashima H. Cancer immunotherapy with lipid nanoparticles loaded with a stimulator of interferon genes agonist against renal tumor lung metastasis Pharmaceutics 16 2023 31 38258042
150 Biber G. Sabag B. Raiff A. Ben-Shmuel A. Puthenveetil A. Benichou J.I.C. Modulation of intrinsic inhibitory checkpoints using nano-carriers to unleash NK cell activity EMBO Mol Med 14 2022 e14073
151 Wei Z.Y. Yi Y. Luo Z. Gong X.Y. Jiang Y.X. Hou D.Y. Selenopeptide nanomedicine activates natural killer cells for enhanced tumor chemoimmunotherapy Adv Mater 34 2022 e2108167
152 Pan S.J. Li T.Y. Tan Y.Z. Xu H.P. Selenium-containing nanoparticles synergistically enhance Pemetrexed&NK cell-based chemoimmunotherapy Biomaterials 280 2022 121321
153 Marciscano A.E. Anandasabapathy N. The role of dendritic cells in cancer and anti-tumor immunity Semin Immunol 52 2021 101481
154 Qin X.H. Zhang M.Z. Zhao Z.P. Du Q. Li Q. Jiang Y. A carrier-free photodynamic nanodrug to enable regulation of dendritic cells for boosting cancer immunotherapy Acta Biomater 147 2022 366 376 35588995
155 Wang P. Wang Y.F. Li H.M. Wang M.M. Wang Y. Wang X.F. A homologous-targeting cGAS-STING agonist multimodally activates dendritic cells for enhanced cancer immunotherapy Acta Biomater 177 2024 400 413 38336268
156 Ma X.Y. Kuang L. Yin Y. Tang L. Zhang Y. Fan Q. Tumor-antigen activated dendritic cell membrane-coated biomimetic nanoparticles with orchestrating immune responses promote therapeutic efficacy against glioma ACS Nano 17 2023 2341 2355 36688797
157 Xu X.D. Wang R. Li D.D. Xiang J.J. Zhang W. Shi X.Y. Guanidine-modified nanoparticles as robust BTZ delivery carriers and activators of immune responses J Control Release 357 2023 310 318 37019286
158 Su L.H. Pan W. Li X.X. Zhou X.Y. Ma X.P. Min Y.Z. Utilizing chemotherapy-induced tumor RNA nanoparticles to improve cancer chemoimmunotherapy Acta Biomater 158 2023 698 707 36563773
159 Sharonov G.V. Serebrovskaya E.O. Yuzhakova D.V. Britanova O.V. Chudakov D.M. B cells, plasma cells and antibody repertoires in the tumour microenvironment Nat Rev Immunol 20 2020 294 307 31988391
160 Fridman W.H. Meylan M. Petitprez F. Sun C.M. Italiano A. Sautès-Fridman C. B cells and tertiary lymphoid structures as determinants of tumour immune contexture and clinical outcome Nat Rev Clin Oncol 19 2022 441 457 35365796
161 He M.Y. Wang M.Y. Xu T. Zhang M.Y. Dai H.X. Wang C. Reactive oxygen species-powered cancer immunotherapy: current status and challenges J Control Release 356 2023 623 648 36868519
162 Yu J.T. Li Q. Wei Z.X. Fan G.L. Wan F.Y. Tian L.L. Ultra-stable MOF@MOF nanoplatform for photodynamic therapy sensitized by relieved hypoxia due to mitochondrial respiration inhibition Acta Biomater 170 2023 330 343 37607616
163 Liu Y.N. Wen Y.Y. Chen X. Zhu X.F. Yu Q.Q. Gong Y.C. Inflammation-responsive functional Ru nanoparticles combining a tumor-associated macrophage repolarization strategy with phototherapy for colorectal cancer therapy J Mater Chem B 7 2019 6210 6223 31566200
164 Zhang L.J. Huang R. Shen Y.W. Liu J. Wu Y. Jin J.M. Enhanced anti-tumor efficacy by inhibiting HIF-1α to reprogram TAMs core-satellite upconverting nanoparticles with curcumin mediated photodynamic therapy Biomater Sci-Uk 9 2021 6403 6415
165 Jian H. Wang X.B. Song P.P. Wu X.Q. Zheng R.X. Wang Y.J. Tumor microcalcification-mediated relay drug delivery for photodynamic immunotherapy of breast cancer Acta Biomater 140 2022 518 529 34923096
166 Tong F. Hu H.L. Xu Y.Y. Zhou Y. Xie R. Lei T. Hollow copper sulfide nanoparticles carrying ISRIB for the sensitized photothermal therapy of breast cancer and brain metastases through inhibiting stress granule formation and reprogramming tumor-associated macrophages Acta Pharm Sin B 13 2023 3471 3488 37655313
167 Choi J. Shim M.K. Yang S. Hwang H.S. Cho H. Kim J. Visible-light-triggered prodrug nanoparticles combine chemotherapy and photodynamic therapy to potentiate checkpoint blockade cancer immunotherapy ACS Nano 15 2021 12086 12098 34165970
168 Liu Y.L. Yang J.X. Liu B. Cao W. Zhang J.P. Yang Y.M. Human iPS cells loaded with MnO2-based nanoprobes for photodynamic and simultaneous enhanced immunotherapy against cancer Nanomicro Lett 12 2020 127 34138126
169 Liu Y. Xun Z.Z. Ma K. Liang S.H. Li X.Y. Zhou S. Identification of a tumour immune barrier in the HCC microenvironment that determines the efficacy of immunotherapy J Hepatol 78 2023 770 782 36708811
170 Horn L.A. Chariou P.L. Gameiro S.R. Qin H.Y. Iida M. Fousek K. Remodeling the tumor microenvironment via blockade of LAIR-1 and TGF-β signaling enables PD-L1-mediated tumor eradication J Clin Invest 132 2022 e155148
171 Peng D.D. Fu M.Y. Wang M.N. Wei Y.Q. Wei X.W. Targeting TGF-β signal transduction for fibrosis and cancer therapy Mol Cancer 21 2022 104 35461253
172 Wang Y. Gao Z.X. Du X.J. Chen S.B. Zhang W.C. Wang J.L. Co-inhibition of the TGF-β pathway and the PD-L1 checkpoint by pH-responsive clustered nanoparticles for pancreatic cancer microenvironment regulation and anti-tumor immunotherapy Biomater Sci-Uk 8 2020 5121 5132
173 Puttock E.H. Tyler E.J. Manni M. Maniati E. Butterworth C. Burger Ramos M. Extracellular matrix educates an immunoregulatory tumor macrophage phenotype found in ovarian cancer metastasis Nat Commun 14 2023 2514 37188691
174 Eide S. Feng Z.P. Doxorubicin chemotherapy-induced "chemo-brain": meta-analysis Eur J Pharmacol 881 2020 173078
175 Yang J. Liang X. Zhai Y.F. Hu X.L. Jia Z.W. Cheng X.L. Considering gemcitabine-based combination chemotherapy as a potential treatment for advanced oesophageal cancer: a meta-analysis of randomised trials Int J Clin Pract 74 2020 e13510
176 Amonkar M.M. Abderhalden L.A. Frederickson A.M. Aksomaityte A. Lang B.M. Leconte P. Clinical outcomes of chemotherapy-based therapies for previously treated advanced colorectal cancer: a systematic literature review and meta-analysis Int J Colorectal Dis 38 2023 10 36630020
177 Wysocki P.J. Lobacz M. Potocki P. Kwinta L. Michalowska-Kaczmarczyk A. Slowik A. Metronomic chemotherapy based on topotecan or topotecan and cyclophosphamide combination (CyTo) in advanced, pretreated ovarian cancer Cancers 15 2023 1067 36831410
178 Hoshitsuki K. Zhou Y.M. Miller A.M. Choi J.K. Swanson H.D. Bhakta N.H. Rituximab administration in pediatric patients with newly diagnosed acute lymphoblastic leukemia Leukemia 37 2023 1782 1791 37543655
179 Fan J.Y. To K.K.W. Chen Z.S. Fu L.W. ABC transporters affects tumor immune microenvironment to regulate cancer immunotherapy and multidrug resistance Drug Resist Update 66 2023 100905
180 Tezcan O. Elshafei A.S. Benderski K. Rama E. Wagner M. Moeckel D. Effect of cellular and microenvironmental multidrug resistance on tumor-targeted drug delivery in triple-negative breast cancer J Control Release 354 2023 784 793 36599395
181 Yasinjan F. Xing Y. Geng H.Y. Guo R. Yang L. Liu Z.L. Immunotherapy: a promising approach for glioma treatment Front Immunol 14 2023 1255611
182 Wu H. Fu X.L. Zhai Y.J. Gao S. Yang X.Y. Zhai G.X. Development of effective tumor vaccine strategies based on immune response cascade reactions Adv Healthc Mater 10 2021 e2100299
183 Jeon E.Y. Choi D.S. Choi S. Won J.Y. Jo Y. Kim H.B. Enhancing adoptive T-cell therapy with fucoidan-based IL-2 delivery microcapsules Bioeng Transl Med 8 2023 e10362
184 Lu D. Chen Y. Jiang M. Wang J. Li Y.T. Ma K.K. KRAS G12V neoantigen specific T cell receptor for adoptive T cell therapy against tumors Nat Commun 14 2023 6389 37828002
185 Lecoq I. Kopp K.L. Chapellier M. Mantas P. Martinenaite E. Perez-Penco M. CCL22-based peptide vaccines induce anti-cancer immunity by modulating tumor microenvironment Oncoimmunology 11 2022 2115655
186 Vajari M.K. Sanaei M.J. Salari S. Rezvani A. Ravari M.S. Bashash D. Breast cancer vaccination: latest advances with an analytical focus on clinical trials Int Immunopharmacol 123 2023 110696
187 Wang G.Q. Zhang Z.L. Zhong K.H. Wang Z. Yang N. Tang X. CXCL11-armed oncolytic adenoviruses enhance CAR-T cell therapeutic efficacy and reprogram tumor microenvironment in glioblastoma Mol Ther 31 2023 134 153 36056553
188 Lin J. Sun S.H. Zhao K. Gao F. Wang R.L. Li Q. Oncolytic parapoxvirus induces gasdermin E-mediated pyroptosis and activates antitumor immunity Nat Commun 14 2023 224 36641456
189 Xiong Z.W. Chan S.L. Zhou J.Y. Vong J.S.L. Kwong T.T. Zeng X.Z. Targeting PPAR-gamma counteracts tumour adaptation to immune-checkpoint blockade in hepatocellular carcinoma Gut 72 2023 1758 1773 37019619
190 Chen D. Varanasi S.K. Hara T. Traina K. Sun M. Mcdonald B. CTLA-4 blockade induces a microglia-Th1 cell partnership that stimulates microglia phagocytosis and anti-tumor function in glioblastoma Immunity 56 2023 2086 2104 37572655
191 Yang W.L. Pang Y.Y. Wang X. Lai Z.H. Lu Y.D. Zheng S.J. A novel CTLA-4 blocking strategy based on nanobody enhances the activity of dendritic cell vaccine-stimulated antitumor cytotoxic T lymphocytes Cel Death Dis 14 2023 406
192 Arance A. de la Cruz-Merino L. Petrella T.M. Jamal R. Ny L. Carneiro A. Phase II LEAP-004 study of lenvatinib plus pembrolizumab for melanoma with confirmed progression on a programmed cell death protein-1 or programmed death ligand 1 inhibitor given as monotherapy or in combination J Clin Oncol 41 2023 75 85 35867951
193 Xiao X.L. Shi J. He C. Bu X. Sun Y.S. Gao M.L. ERK and USP5 govern PD-1 homeostasis via deubiquitination to modulate tumor immunotherapy Nat Commun 14 2023 2859 37208329
194 Wu H.B. Guo C.C. Wang C.Y. Xu J. Zheng S.Y. Duan J. Single-cell RNA sequencing reveals tumor heterogeneity, microenvironment, and drug-resistance mechanisms of recurrent glioblastoma Cancer Sci 114 2023 2609 2621 36853018
195 Yuan Z.N. Li Y.P. Zhang S.F. Wang X.Y. Dou H. Yu X. Extracellular matrix remodeling in tumor progression and immune escape: from mechanisms to treatments Mol Cancer 22 2023 48 36906534
196 Tajaldini M. Poorkhani A. Amiriani T. Amiriani A. Javid H. Aref P. Strategy of targeting the tumor microenvironment via inhibition of fibroblast/fibrosis remodeling new era to cancer chemo-immunotherapy resistance Eur J Pharmacol 957 2023 175991
197 Davern M. Donlon N.E. Power R. Hayes C. King R. Dunne M.R. The tumour immune microenvironment in oesophageal cancer Br J Cancer 125 2021 479 494 33903730
198 Jia Y.B. Hu J. Zhu C.J. Li Z.J. Yang X.Y. Liu R.T. Engineered NanoAlum from aluminum turns cold tumor hot for potentiating cancer metalloimmunotherapy J Control Release 354 2023 770 783 36702259
199 Zhou F. Li X.J.Y. Xue X.Y. Li S. Fan G.F. Cai Y.J. A novel tri-functional liposome re-educates "cold tumor" and abrogates tumor growth by synergizing autophagy inhibition and PD-L1 blockade Adv Healthc Mater 12 2023 e2202757
200 Duan Q.Q. Zhang H.L. Zheng J.N. Zhang L.J. Turning cold into hot: firing up the tumor microenvironment Trends Cancer 6 2020 605 618 32610070
201 Ni J.J. Zhang Z.Z. Ge M.J. Chen J.Y. Zhuo W. Immune-based combination therapy to convert immunologically cold tumors into hot tumors: an update and new insights Acta Pharmacol Sin 44 2023 288 307 35927312
202 Chaturvedi V.K. Singh A. Singh V.K. Singh M.P. Cancer nanotechnology: a new revolution for cancer diagnosis and therapy Curr Drug Metab 20 2019 416 429 30227814
203 Nasrollahpour H. Khalilzadeh B. Hasanzadeh M. Rahbarghazi R. Estrela P. Naseri A. Nanotechnology-based electrochemical biosensors for monitoring breast cancer biomarkers Med Res Rev 43 2023 464 569 36464910
204 Hegde M. Naliyadhara N. Unnikrishnan J. Alqahtani M.S. Abbas M. Girisa S. Nanoparticles in the diagnosis and treatment of cancer metastases: current and future perspectives Cancer Lett 556 2023 216066
205 Huang C. Xie T. Liu Y.F. Yan S. OuYang F.J. Zhang H.T. A sodium alginate-based multifunctional nanoplatform for synergistic chemo-immunotherapy of hepatocellular carcinoma Adv Mater 35 2023 e2301352
206 Wang H. Chen Y. Wei R. Zhang J.L. Zhu J.H. Wang W.B. Synergistic chemoimmunotherapy augmentation via sequential nanocomposite hydrogel-mediated reprogramming of cancer-associated fibroblasts in osteosarcoma Adv Mater 36 2024 e2309591
207 Barnwal A. Ganguly S. Bhattacharyya J. Multifaceted Nano-DEV-IL for sustained release of IL-12 to avert the immunosuppressive tumor microenvironment and IL-12-associated toxicities Acs Appl Mater Inter 15 2023 20012 20026
208 Hemmatpour H. Haddadi-Asl V. Burgers T.C.Q. Yan F. Stuart M.C.A. Reker-Smit C. Temperature-responsive and biocompatible nanocarriers based on clay nanotubes for controlled anti-cancer drug release Nanoscale 15 2023 2402 2416 36651239
209 Zhong H.P. Li X.W. Yu N. Zhang X. Mu J.Q. Liu T. Fine-tuning the sequential drug release of nano-formulated mutual prodrugs dictates the combination effects Chem Sci 14 2023 3789 3799 37035705
210 Wang C. Li Q.S. Xiao J. Liu Y. Nanomedicine-based combination therapies for overcoming temozolomide resistance in glioblastomas Cancer Biol Med 20 2023 325 343 37144620
211 Lu Y. Pan Q.Q. Gao W.X. Pu Y.J. He B. Reversal of cisplatin chemotherapy resistance by glutathione-resistant copper-based nanomedicine cuproptosis J Mater Chem B 10 2022 6296 6306 35904024
212 Huffman B.M. Mallick A.B. Horick N.K. Wang-Gillam A. Hosein P.J. Morse M.A. Effect of a MUC5AC antibody (NPC-1C) administered with second-line gemcitabine and nab-paclitaxel on the survival of patients with advanced pancreatic ductal adenocarcinoma: a randomized clinical trial Jama Netw Open 6 2023 e2249720
213 Milano G. Innocenti F. Minami H. Liposomal irinotecan (Onivyde): exemplifying the benefits of nanotherapeutic drugs Cancer Sci 113 2022 2224 2231 35445479
214 Li Q.Q. Shi Z.Q. Zhang F. Zeng W.W. Zhu D.W. Mei L. Symphony of nanomaterials and immunotherapy based on the cancer-immunity cycle Acta Pharm Sin B 12 2022 107 134 35127375
215 Yan J. Li W.X. Tian H. Li B. Yu X.Y. Wang G.H. Metal-phenolic nanomedicines regulate T-cell antitumor function for sono-metabolic cancer therapy Acs Nano 17 2023 14667 14677 37486249
216 Zhan M.S. Qiu J.R. Fan Y. Chen L. Guo Y.Q. Wang Z.Q. Phosphorous dendron micelles as a nanomedicine platform for cooperative tumor chemoimmunotherapy via synergistic modulation of immune cells Adv Mater 35 2023 e2208277
217 Li L.G. Yang X.X. Xu H.Z. Yu T.T. Li Q.R. Hu J. A dihydroartemisinin-loaded nanoreactor motivates anti-cancer immunotherapy by synergy-induced ferroptosis to activate cgas/STING for reprogramming of macrophage Adv Healthc Mater 12 2023 e2301561
218 Wu Y.P. Chang X.W. Yang G.Z. Chen L. Wu Q. Gao J.M. A physiologically responsive nanocomposite hydrogel for treatment of head and neck squamous cell carcinoma via proteolysis-targeting chimeras enhanced immunotherapy Adv Mater 35 2023 e2210787
219 Hu L.J. Huang S.C. Chen G.J. Li B. Li T. Lin M.Z. Nanodrugs incorporating LDHA siRNA inhibit M2-like polarization of TAMs and amplify autophagy to assist oxaliplatin chemotherapy against colorectal cancer Acs Appl Mater Inter 14 2022 31625 31633
220 Han X. Wei Q. Lv Y. Weng L. Huang H.Y. Wei Q.Y. Ginseng-derived nanoparticles potentiate immune checkpoint antibody efficacy by reprogramming the cold tumor microenvironment Mol Ther 30 2022 327 340 34450250
221 Xu H.Z. Li T.F. Wang C. Ma Y. Liu Y. Zheng M.Y. Synergy of nanodiamond-doxorubicin conjugates and PD-L1 blockade effectively turns tumor-associated macrophages against tumor cells J Nanobiotechnol 19 2021 268
222 Huis In 't Veld R.V. Da Silva C.G. Jager M.J. Cruz L.J. Ossendorp F. Combining photodynamic therapy with immunostimulatory nanoparticles elicits effective anti-tumor immune responses in preclinical murine models Pharmaceutics 13 2021 1470 34575546
223 Kim J. Cho H. Lim D.K. Joo M.K. Kim K. Perspectives for improving the tumor targeting of nanomedicine via the EPR effect in clinical tumors Int J Mol Sci 24 2023 10082
224 Lim E.K. Chung B.H. Chung S.J. Recent advances in pH-sensitive polymeric nanoparticles for smart drug delivery in cancer therapy Curr Drug Targets 19 2018 300 317 27262486
225 Guo B.D. Yang F.Y. Zhang L.P. Zhao Q.X. Wang W.K. Yin L. Cuproptosis induced by ROS responsive nanoparticles with elesclomol and copper combined with αPD-L1 for enhanced cancer immunotherapy Adv Mater 35 2023 e2212267
226 Yu N.Y. Ding M.B. Li J.C. Near-infrared photoactivatable immunomodulatory nanoparticles for combinational immunotherapy of cancer Front Chem 9 2021 701427
227 Ali M. What function of nanoparticles is the primary factor for their hyper-toxicity? Adv Colloid Interfac 314 2023 102881
228 Abulikemu A. Zhao X.Y. Xu H.L. Li Y. Ma R. Yao Q. Silica nanoparticles aggravated the metabolic associated fatty liver disease through disturbed amino acid and lipid metabolisms-mediated oxidative stress Redox Biol 59 2023 102569
229 Sun M.Q. Zhang J.Y. Liang S. Du Z. Liu J.Y. Sun Z.W. Metabolomic characteristics of hepatotoxicity in rats induced by silica nanoparticles Ecotox Environ Safe 208 2021 111496
230 Pei X.Y. Tang S.S. Jiang H.Y. Zhang W.J. Xu G. Zuo Z.H. Paeoniflorin recued hepatotoxicity under zinc oxide nanoparticles exposure via regulation on gut-liver axis and reversal of pyroptosis Sci Total Environ 904 2023 166885
231 Ali A. Saeed S. Hussain R. Afzal G. Siddique A. Parveen G. Synthesis and characterization of silica, silver-silica, and zinc oxide-silica nanoparticles for evaluation of blood biochemistry, oxidative stress, and hepatotoxicity in albino rats Acs Omega 8 2023 20900 20911 37332821
232 He K.Y. Tang M. Safety of novel liposomal drugs for cancer treatment: advances and prospects Chem Biol Interact 295 2018 13 19 28919304
233 Paris J.L. Baeza A. Vallet-Regí M. Overcoming the stability, toxicity, and biodegradation challenges of tumor stimuli-responsive inorganic nanoparticles for delivery of cancer therapeutics Expert Opin Drug Deliv 16 2019 1095 1112 31469003
234 Haugh A.M. Probasco J.C. Johnson D.B. Neurologic complications of immune checkpoint inhibitors Expert Opin Drug Saf 19 2020 479 488 32126176
235 Wright J.J. Powers A.C. Johnson D.B. Endocrine toxicities of immune checkpoint inhibitors Nat Rev Endocrinol 17 2021 389 399 33875857
236 Iwama S. Kobayashi T. Yasuda Y. Arima H. Immune checkpoint inhibitor-related thyroid dysfunction Best Pract Res Clin Endocrinol Metab 36 2022 101660
